daunorubicin~|~kidney failure, chronic~|~unconscious state~|~apnea~|~cardiac arrest~|~do-not-resuscitate orders~|~pisum sativum~|~phosphoethanolamine~|~absent pulse~|~agonal respiration~|~apnea, ctcae~|~arrested progression~|~asystole by ecg finding~|~asystole, ctcae 3.0~|~asystole, ctcae 5.0~|~before~|~cdisc events class~|~dnr - do not resuscitate~|~do not resuscitate:find:pt:{setting}:doc:{role}~|~electromechanical dissociation~|~encounter due to problems related to other legal circumstances - arrest~|~estimated~|~etiology~|~etiology aspects~|~event~|~event unit~|~law enforcement arrest~|~leading~|~medical~|~medical referral type~|~medical school type~|~medical service~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pea preparation~|~peas - dietary~|~pharmaceutical preparations~|~pisum sativum (pea) extract~|~science of etiology~|~pea allergenic extract~|~chronic kidney disease stage 5~|~unconscious personality factor
calcium channel blockers~|~digoxin~|~adrenergic beta-antagonists~|~syncope~|~age of onset~|~seizures~|~clonidine~|~dizziness~|~chest pain~|~artificial cardiac pacemaker~|~pulmonary edema~|~heart diseases~|~acute - triage code~|~admission level of care code - acute~|~before~|~cdisc events class~|~calcium channel antagonists [moa]~|~digoxin measurement~|~etiology~|~etiology aspects~|~event~|~event unit~|~have you felt weak (question)~|~medical~|~medical referral type~|~medical school type~|~medical service~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~onset of (contextual qualifier)~|~pacemaker ecg assessment~|~pacemaker procedure~|~pacemakers~|~pharmaceutical preparations~|~pulmonary edema, ctcae~|~science of etiology~|~seizure, ctcae 3.0~|~seizure, ctcae 5.0~|~specimen source codes - pacemaker~|~syncope (amphibian)~|~syncope, ctcae 5.0~|~weak~|~weakness~|~acute~|~acute inpatient encounter~|~cholinergic~|~abnormal mental state~|~chest pain:finding:point in time:^patient:ordinal
sepsis~|~communicable diseases~|~chest pain~|~ablepharon-macrostomia syndrome~|~congestive heart failure~|~septicemia~|~allergens~|~hemorrhage~|~hypotension~|~pulmonary edema~|~trauma~|~accelerator mass spectrometry~|~act relationship subset - previous~|~actual blood loss~|~adverse event associated with infection~|~allergen (brand of diphenylpyraline)~|~blood loss~|~choroidal fissure~|~etiology~|~etiology aspects~|~exposure to~|~history of present illness~|~hypotension, ctcae~|~induce (action)~|~infection~|~medical~|~medical history~|~medical referral type~|~medical school type~|~medical service~|~past history of~|~previous~|~pulmonary edema, ctcae~|~science of etiology~|~sepsis (invertebrate)~|~sepsis, ctcae~|~twist2 wt allele~|~trauma, nursing specialty~|~traumatic injury~|~wounds and injuries~|~trauma qualifier~|~aspects of signs~|~chest pain:finding:point in time:^patient:ordinal~|~manufactured sign~|~no evidence of~|~physical findings
angina pectoris~|~acute chest syndrome~|~myocardial infarction~|~pain~|~acute coronary syndrome~|~jaw~|~erectile dysfunction~|~american cancer society~|~acute myocardial infarction~|~ever told by doctor that you had angina:finding:point in time:^patient:ordinal~|~accs gene~|~acs - activity card sort~|~acss2 gene~|~acute myocardial infarction pathway~|~acute myocardial infarction by ecg finding~|~american college of surgeons~|~ami <spider>~|~anterior myocardial infarction~|~co-methylating acetyl-coa synthase activity~|~chest discomfort~|~entire jaw region~|~epigastric discomfort~|~epigastric fullness~|~equivalent weight~|~erectile dysfunction, ctcae~|~etiology~|~etiology aspects~|~exertion~|~family history~|~gdc ajcc clinical stage terminology~|~in addition to~|~jaw device~|~medical~|~medical referral type~|~medical school type~|~medical service~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pla2g15 gene~|~pharmaceutical preparations~|~recent~|~science of etiology~|~with - dosing instruction fragment~|~acetate-coa ligase activity~|~administration method - pain~|~adverse event associated with pain~|~age~|~age:time:point in time:^patient:quantitative~|~baresthesia~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~pressure (finding)~|~pressure (property)~|~pressure - action~|~pressure- physical agent~|~upper abdominal pain~|~usual severity pain
cold temperature~|~apnea~|~ethanol~|~barbiturates~|~environment~|~drug abuse~|~submersion~|~alcohols~|~immersion~|~absent pulse~|~agonal respiration~|~alcohol - recreational drug use code~|~apnea, ctcae~|~barbiturates measurement~|~electrocardiogram finding~|~environmental~|~ethanol measurement~|~etiology~|~etiology aspects~|~exposure to~|~hypothermia (central) (local)~|~hypothermia due to exposure~|~hypothermia, ctcae~|~hypothermia, natural~|~immersion investigative technique~|~immersion route of exposure~|~medical~|~medical referral type~|~medical school type~|~medical service~|~poisoning by, adverse effect of and underdosing of barbiturates~|~science of etiology~|~evidence of (contextual qualifier)
adenosine~|~supraventricular tachycardia~|~wolff-parkinson-white syndrome~|~history of present illness~|~medical history~|~past history of~|~cardiac flutter~|~electrocardiogram finding~|~fbl gene~|~flutter (respiratory device)~|~supraventricular tachycardia by ecg finding~|~use of
adenosine~|~supraventricular tachycardia~|~wolff-parkinson-white syndrome~|~pulmonary edema~|~history of present illness~|~medical history~|~past history of~|~cardiac flutter~|~electrocardiogram finding~|~fbl gene~|~flutter (respiratory device)~|~pulmonary edema, ctcae~|~supraventricular tachycardia by ecg finding~|~use of
cardiac arrest~|~patients~|~cardiac arrest, ctcae 5~|~disabled person code - patient~|~electrocardiogram finding~|~in addition to~|~mail claim party - patient~|~relationship modifier - patient~|~report source - patient~|~specimen source codes - patient~|~specimen type - patient~|~veterinary patient~|~with - dosing instruction fragment
polyvinyl chloride~|~patient discharge~|~myocardial infarction~|~coronary artery disease~|~premature ventricular contractions~|~vertigo~|~chest pain~|~central nervous system stimulants~|~defibrillators~|~bradycardia~|~computer assisted diagnosis~|~dyspnea~|~cardiac arrhythmia~|~diabetes mellitus~|~dizziness~|~congestive heart failure~|~dffb protein, human~|~cardiomyopathies~|~implanted medical device (finding)~|~implants~|~chest pain:finding:point in time:^patient:ordinal~|~heart~|~acod1 gene~|~absent~|~acute myocardial infarction~|~ami <spider>~|~anterior myocardial infarction~|~b4galnt2 gene~|~bradycardia by ecg finding~|~cad gene~|~cald1 wt allele~|~caddo language~|~cardiac - anatomy qualifier~|~central nervous system stimulant [epc]~|~choroidal fissure~|~collision-induced dissociation~|~couples (persons)~|~dffb gene~|~dffb wt allele~|~diabetes~|~dizziness, ctcae 3.0~|~dizziness, ctcae 5.0~|~dyspnea, ctcae~|~have dizziness~|~how much distress dizziness~|~how often dizzy~|~hypertension, ctcae~|~hypertensive disease~|~in addition to~|~pacerr gene~|~rubcnl gene~|~recent~|~stent, device~|~stimulant~|~triplet multiple birth~|~usual severity dizziness~|~weakness~|~with - dosing instruction fragment~|~cyclophosphamide/dacarbazine/doxorubicin protocol~|~cytarabine/daunorubicin protocol~|~body fluid discharge~|~discharge, body substance, sample~|~discharge, body substance~|~evidence of (contextual qualifier)~|~irregular~|~specimen source codes - discharge~|~usage~|~use - dosing instruction imperative~|~ventricular premature complex by ecg finding~|~cisplatin/cyclophosphamide/etoposide protocol~|~late endosome~|~utilization qualifier
equine gonadotropins~|~daunorubicin~|~tachycardia, ventricular~|~kidney failure, chronic~|~electrocardiography~|~ventricular fibrillation~|~drug overdose~|~do-not-resuscitate orders~|~electrocardiogram~|~epicatechin-3-gallate~|~cardiac arrest~|~absent pulse~|~agonal respiration~|~arrested progression~|~before~|~cdisc events class~|~dnr - do not resuscitate~|~do not resuscitate:find:pt:{setting}:doc:{role}~|~encounter due to problems related to other legal circumstances - arrest~|~estimated~|~event~|~event unit~|~law enforcement arrest~|~leading~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pharmaceutical preparations~|~suspected diagnosis~|~suspected qualifier~|~ventricular fibrillation by ecg finding~|~ventricular fibrillation, ctcae 3.0~|~ventricular fibrillation, ctcae 5.0~|~ventricular tachycardia by ecg finding~|~ventricular tachycardia, ctcae 3.0~|~ventricular tachycardia, ctcae 5.0~|~chronic kidney disease stage 5~|~event qualification - overdose~|~overdose
coronary artery disease~|~syncope~|~computer assisted diagnosis~|~diet therapy~|~artificial cardiac pacemaker~|~congestive heart failure~|~dffb protein, human~|~defibrillators~|~diet~|~presyncope~|~cardiomyopathies~|~pharmaceutical preparations~|~acod1 gene~|~b4galnt2 gene~|~cad gene~|~cald1 wt allele~|~caddo language~|~choroidal fissure~|~collision-induced dissociation~|~dffb gene~|~dffb wt allele~|~drugs - dental services~|~electrocardiogram finding~|~medical history~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pmh - past medical history~|~pacemaker ecg assessment~|~pacemaker procedure~|~pacemakers~|~palpitations~|~palpitations, ctcae~|~specimen source codes - pacemaker~|~syncope (amphibian)~|~syncope, ctcae 5.0~|~cyclophosphamide/dacarbazine/doxorubicin protocol~|~cytarabine/daunorubicin protocol~|~basal diet~|~diet (animal life circumstance)~|~special diet therapy~|~sustained~|~diet - supply
patient discharge~|~coronary artery disease~|~defibrillators~|~computer assisted diagnosis~|~cardiac arrhythmia~|~diabetes mellitus~|~chest pain~|~congestive heart failure~|~dffb protein, human~|~cardiomyopathies~|~implanted medical device (finding)~|~implants~|~heart~|~acod1 gene~|~b4galnt2 gene~|~cad gene~|~cald1 wt allele~|~caddo language~|~cardiac - anatomy qualifier~|~choroidal fissure~|~collision-induced dissociation~|~dffb gene~|~dffb wt allele~|~diabetes~|~electrocardiogram finding~|~hypertension, ctcae~|~hypertensive disease~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pacerr gene~|~pharmaceutical preparations~|~rubcnl gene~|~recent~|~stent, device~|~cyclophosphamide/dacarbazine/doxorubicin protocol~|~cytarabine/daunorubicin protocol~|~body fluid discharge~|~chest pain:finding:point in time:^patient:ordinal~|~discharge, body substance, sample~|~discharge, body substance~|~specimen source codes - discharge~|~sustained
cold temperature~|~shivering~|~pain~|~bradycardia~|~sepsis~|~ethanol~|~barbiturates~|~flatulence~|~septicemia~|~submersion~|~glycation end products, advanced~|~andorra~|~chills~|~cyanosis~|~shock~|~exposure to~|~alcohols~|~congenital abnormality~|~immersion~|~accident due to exposure to weather conditions~|~alcohol - recreational drug use code~|~and~|~and - dosing instruction fragment~|~barbiturates measurement~|~bradycardia by ecg finding~|~cyanosis, ctcae~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~environmental wind~|~ethanol measurement~|~exposure domain~|~immersion investigative technique~|~immersion route of exposure~|~infection~|~infections of musculoskeletal system~|~infections:-:point in time:^patient:-~|~injury due to exposure to external cause~|~old~|~old episode~|~poisoning by, adverse effect of and underdosing of barbiturates~|~relationshipconjunction - and~|~sensory (qualifier value)~|~sepsis (invertebrate)~|~sepsis, ctcae~|~very~|~very much~|~wetness~|~teratologic~|~abnormal mental state~|~administration method - pain~|~adverse event associated with pain~|~antimicrobial susceptibility result~|~drug usage~|~extreme~|~extreme response~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~predisposition -- attribute~|~susceptible~|~usual severity pain~|~very severe~|~young
water~|~drinking water~|~submersion~|~dyspnea~|~cardiopulmonary arrest~|~vomiting~|~pulmonary edema~|~water - specimen source codes~|~water specimen~|~immersion~|~trauma~|~deep (qualifier value)~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~dyspnea, ctcae~|~hypothermia (central) (local)~|~hypothermia due to exposure~|~hypothermia, ctcae~|~hypothermia, natural~|~immersion investigative technique~|~immersion route of exposure~|~mental status change~|~pulmonary edema, ctcae~|~regardless~|~trauma, nursing specialty~|~traumatic injury~|~without~|~wounds and injuries~|~around~|~trauma qualifier~|~bothered by vomiting~|~have been vomiting~|~how much distress vomiting~|~how often vomiting~|~possible~|~possible diagnosis~|~possibly related to intervention~|~usual severity vomiting~|~vomiting, ctcae
risk~|~dental occlusion~|~urticaria~|~erythema~|~identification (psychology)~|~pruritus~|~communicable diseases~|~tetanus~|~insecta~|~allergic reaction~|~animals, domestic~|~andorra~|~contusions~|~hypotension~|~edema~|~exanthema~|~bite (event)~|~cep70 gene~|~specimen source codes - bite~|~sting injury~|~tmem173 gene~|~tmem173 wt allele~|~bite injury~|~hypersensitivity~|~patients~|~animals~|~time~|~act relationship subset - previous~|~adverse event associated with infection~|~allergic reaction, ctcae~|~anatomic site~|~and~|~and - dosing instruction fragment~|~applicable~|~bruising, ctcae~|~cdisc sdtm size terminology~|~description~|~disabled person code - patient~|~domestic~|~facilitated oscillatory release technique~|~gdc type terminology~|~home environment~|~hypotension, ctcae~|~identified~|~in addition to~|~infection~|~insect extract~|~insect specimen code~|~involvement with~|~location~|~location of oral residue following swallowing~|~location of pharyngeal residue following swallowing~|~mail claim party - patient~|~material identification~|~medical device break~|~not applicable~|~preposition for~|~previous~|~product description/appearance~|~rabies (disorder)~|~reaction~|~red color~|~redness~|~relationship modifier - patient~|~relationshipconjunction - and~|~report source - patient~|~sgcg gene~|~specimen source codes - patient~|~specimen type - patient~|~stinging sensation~|~subject risk~|~transaction counts and value totals - location~|~type - parameterizeddatatype~|~type - attribute~|~veterinary patient~|~wwox gene~|~wwox wt allele~|~wild~|~with - dosing instruction fragment~|~without~|~location participation type~|~size~|~size - solid dosage form~|~tetanus toxoid vaccine, inactivated~|~burning sensation~|~burning sensation quality~|~data types - time~|~evidence of (contextual qualifier)~|~have itch~|~how much distress itching~|~how often itching~|~smoking method of administration~|~swelling~|~time (foundation metadata concept)~|~usual severity itching~|~value type - time~|~wound pain
temperature~|~sweating~|~muscle cramp~|~tachycardia~|~vertigo~|~seizures~|~ethanol~|~dizziness~|~environment~|~ability~|~fever~|~regulation~|~syncopal episode~|~thyroid (usp)~|~glycation end products, advanced~|~exposure to~|~andorra~|~thyroid gland~|~fatigue~|~recent~|~very~|~very much~|~alcohols~|~thyroid diseases~|~absent~|~accident due to exposure to weather conditions~|~alcohol - recreational drug use code~|~and~|~and - dosing instruction fragment~|~cramping sensation quality~|~dizziness, ctcae 3.0~|~dizziness, ctcae 5.0~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~ethanol measurement~|~exertion~|~exhaustion~|~exposure domain~|~have dizziness~|~how much distress dizziness~|~how often dizzy~|~hydration status~|~hydration status:finding:point in time:^patient:nominal~|~illness (finding)~|~increase~|~increased~|~injury due to exposure to external cause~|~medications~|~old~|~old episode~|~pharmaceutical preparations~|~regulation of biological process~|~relationshipconjunction - and~|~thyroid diagnostic radiopharmaceuticals~|~tachycardia by ecg finding~|~traumatic and/or non-traumatic injury~|~traumatic injury~|~usual severity dizziness~|~weakness~|~hyperthermia treatment~|~medication - hl7 publishing domain~|~abnormal mental state~|~and/or~|~antimicrobial susceptibility result~|~drug usage~|~fatigue subordinate domain~|~fatigue, ctcae 5.0~|~feel fatigue~|~high humidity~|~lengthened (qualifier value)~|~predisposition -- attribute~|~prolonged~|~prolonged release mechanism of action~|~susceptible~|~young
pain~|~myalgia~|~vomiting~|~blood~|~gastroesophageal reflux disease~|~muscle cramp~|~movement~|~abdominal pain~|~diarrhea~|~electromagnetic radiation~|~family~|~peritonitis~|~dysuria~|~headache~|~flank pain~|~constipation~|~heartburn~|~nausea~|~symptoms~|~fever~|~radiating pain~|~emesis (eukaryote)~|~emesis [pe]~|~vomitus~|~history~|~pathological dilatation~|~diarrhea, ctcae~|~have diarrhea~|~how much distress diarrhea~|~how often diarrhea~|~in addition to~|~increase~|~increased~|~usual severity diarrhea~|~with - dosing instruction fragment~|~administration method - pain~|~adverse event associated with pain~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~usual severity pain~|~radiation~|~friend~|~travel~|~abdomen distended~|~abdominal bloating~|~acid reflux~|~anatomic site~|~associated symptom~|~bloating, ctcae~|~bothered by nausea~|~bowl dosing unit~|~bowling (activity)~|~bowls (device)~|~changed status~|~changing~|~concept history~|~constant (qualifier)~|~constant - dosing instruction fragment~|~constipation, ctcae~|~cough frequency~|~cough, ctcae~|~coughing~|~coverage level - family~|~cramping sensation quality~|~distention~|~dull~|~dull pain~|~dull sensation quality~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~dysuria, ctcae~|~entity name part type - family~|~etiology~|~etiology aspects~|~family (taxonomic)~|~family collection~|~feel nausea~|~friends - (religious affiliation)~|~have been coughing~|~have constipation~|~have nausea~|~headache, ctcae~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~how much distress constipation~|~how much distress cough~|~how much distress nausea~|~how much nausea during this period~|~how often constipation~|~how often nausea~|~improvement~|~in blood~|~intermittent~|~last~|~last name~|~living arrangement - family~|~location~|~location of oral residue following swallowing~|~location of pharyngeal residue following swallowing~|~malaise~|~malaise, ctcae~|~medical~|~medical history~|~medical referral type~|~medical school type~|~medical service~|~menstrual history~|~nausea subscale~|~nausea visual analogue scale~|~nausea, ctcae 3.0~|~nausea, ctcae 5.0~|~nausea:presence or threshold:point in time:^patient:ordinal~|~palpitations~|~patient outcome - worsening~|~radiation ionizing radiotherapy~|~radiotherapy research~|~rash and dermatitis associated with radiation excluding chemoradiation, ctcae~|~rebound tenderness~|~recent injury~|~spen gene~|~spen wt allele~|~science of etiology~|~sharp sensation quality~|~similarity~|~symptoms aspect~|~therapeutic radiology procedure~|~transaction counts and value totals - location~|~unit of radiation dose~|~usual severity constipation~|~usual severity cough~|~usual severity nausea~|~weakness~|~worse~|~worsening pattern~|~location participation type~|~peripheral blood~|~surgical history~|~travel charge~|~abdominal pain, ctcae 5~|~bothered by vomiting~|~fever symptoms (finding)~|~fever, ctcae~|~flank pain, ctcae~|~have been vomiting~|~how much distress vomiting~|~how often vomiting~|~time of last food intake~|~usual severity vomiting~|~vomiting, ctcae
hallucinations~|~confusion~|~violence~|~drug overdose~|~diabetes mellitus~|~receptor for advanced glycation endproducts~|~delusions~|~fever~|~mok protein, human~|~rage~|~self-injurious behavior~|~anxiety~|~anger~|~anxiety disorders~|~gene expression~|~aggression scale (basc-2)~|~aggressive behavior~|~agitation~|~agitation, ctcae 3.0~|~agitation, ctcae 5.0~|~anxiety scale (basc-2)~|~anxiety visual analogue scale~|~anxiety, ctcae 3.0~|~anxiety, ctcae 5.0~|~bizarre behavior~|~change -- procedure~|~changed status~|~changing~|~clouded consciousness~|~confusion, ctcae 3.0~|~confusion, ctcae 5.0~|~crisis~|~delta (difference)~|~diabetes~|~expression (foundation metadata concept)~|~expression - value symbols~|~expression procedure~|~hallucinations, ctcae~|~homicidal thoughts~|~known~|~medical~|~medical referral type~|~medical school type~|~medical service~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~mental disorders~|~others - allergy~|~pharmaceutical preparations~|~substance abuse problem~|~suicidal~|~combative~|~hyperthermia treatment~|~other medicated shampoos in atc~|~threat~|~violent~|~ager gene~|~ager wt allele~|~absence of pain sensation~|~affect (mental function)~|~event qualification - overdose~|~fear (mental process)~|~mok gene~|~mok wt allele~|~overdose~|~pain sensitivity quantitative trait locus 1~|~self-harm
urticaria~|~age of onset~|~deglutition disorders~|~dyspnea~|~erythema~|~pruritus~|~ablepharon-macrostomia syndrome~|~food allergy~|~insect sting~|~allergens~|~andorra~|~chest~|~exanthema~|~history~|~hypotension~|~shock~|~exposure to~|~accelerator mass spectrometry~|~accident due to exposure to weather conditions~|~act relationship subset - previous~|~allergen (brand of diphenylpyraline)~|~anatomic site~|~and~|~and - dosing instruction fragment~|~anterior thoracic region~|~concept history~|~cutaneous route of drug administration~|~dermal - anatomy qualifier~|~dyspnea, ctcae~|~eruptions~|~exposure domain~|~feeling of throat tightness~|~food allergy allergen~|~have difficulty swallowing~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~how much distress difficulty swallowing~|~how often difficulty swallowing~|~hypotension, ctcae~|~ige-mediated food allergy~|~injury due to exposure to external cause~|~location~|~location of oral residue following swallowing~|~location of pharyngeal residue following swallowing~|~medical history~|~medications~|~onset of (contextual qualifier)~|~pharmaceutical preparations~|~previous~|~recent~|~red color~|~redness~|~relationshipconjunction - and~|~twist2 wt allele~|~toxic effect of venom~|~transaction counts and value totals - location~|~usual severity difficulty swallowing~|~location participation type~|~medication - hl7 publishing domain~|~have itch~|~how much distress itching~|~how often itching~|~insect sting preparation~|~usual severity itching~|~wheezing stridor
lethargy~|~dehydration~|~desiccation~|~hyperglycemia~|~hypoglycemia~|~irritable mood~|~negative surgical margin~|~pharmaceutical preparations~|~skin~|~bizarre behavior~|~cdisc events class~|~clear~|~cool - action~|~decreased~|~decreasing~|~dehydration procedure~|~dehydration, ctcae~|~diaphoretic~|~entire skin~|~epidermal cgvhd score 0~|~event~|~event unit~|~feels warm~|~glucose in blood specimen above reference range~|~hyperglycemia, ctcae~|~hypoglycemia, ctcae~|~irritability, ctcae~|~irritation - emotion~|~kussmaul's respiration~|~lethargy, ctcae~|~mechanism (attribute)~|~mechanism component of device~|~medical history~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~mental status, ctcae~|~mental state~|~mental status:finding:point in time:^patient:narrative:observed~|~mental status:finding:point in time:^patient:nominal:observed~|~pmh - past medical history~|~pharmacologic substance~|~recent~|~reduced~|~regulatory report~|~remote control command - clear~|~report (document)~|~report:finding:point in time:{setting}:document:{role}~|~reporting~|~skin specimen~|~skin specimen source code~|~skin, human~|~specimen condition - cool~|~unresponsive to treatment~|~without~|~toxic ingestion~|~unresponsive behavior~|~warming process~|~aspects of signs~|~dry~|~dry skin~|~dryness (characteristic)~|~entity handling - dry~|~hhat gene~|~illicit medication use~|~manufactured sign~|~manufactured ski~|~physical findings~|~ski anatomical site notation for tumour staging~|~ski gene~|~special handling code - dry
paresthesia~|~post-traumatic stress disorder~|~hyperventilation~|~hand~|~andorra~|~anxiety~|~anxiety disorders~|~agitation~|~agitation, ctcae 3.0~|~agitation, ctcae 5.0~|~and~|~and - dosing instruction fragment~|~anxiety scale (basc-2)~|~anxiety visual analogue scale~|~anxiety, ctcae 3.0~|~anxiety, ctcae 5.0~|~carpopedal spasm~|~crisis~|~has tingling sensation~|~history of present illness~|~medical history~|~past history of~|~perioral~|~recent~|~relationshipconjunction - and~|~traumatic event
epistaxis~|~hematemesis~|~hemoptysis~|~abdominal pain~|~hematochezia~|~vomiting~|~blood coagulation disorders~|~blood platelet disorders~|~contusions~|~hemorrhage~|~hypovolemia~|~massive~|~actual blood loss~|~blood loss~|~bloody~|~bruising, ctcae~|~coffee ground vomiting~|~due to~|~epistaxis, ctcae~|~etiology~|~etiology aspects~|~extensive~|~hemophilia, nos~|~hemorrhagic~|~individual cancer history~|~is there a cancer history~|~medical~|~medical referral type~|~medical school type~|~medical service~|~science of etiology~|~abdominal pain, ctcae 5~|~blood in stool~|~bothered by vomiting~|~have been vomiting~|~how big a problem is bloody stools~|~how much distress vomiting~|~how often vomiting~|~low platelet count~|~rectal hemorrhage~|~secondary to~|~usual severity vomiting~|~vomiting, ctcae~|~anticoagulant use
oliguria~|~poverty~|~tachycardia~|~vertigo~|~dizziness~|~desiccation~|~alcohol abuse~|~anorexia~|~diarrhea~|~nausea~|~vomiting~|~hypovolemia~|~malnutrition~|~mucous membrane~|~anorexia, ctcae~|~bothered by nausea~|~compensated~|~decreased urine output~|~diarrhea, ctcae~|~dizziness, ctcae 3.0~|~dizziness, ctcae 5.0~|~exertion~|~feel nausea~|~have diarrhea~|~have dizziness~|~have nausea~|~how much distress diarrhea~|~how much distress dizziness~|~how much distress nausea~|~how much nausea during this period~|~how often diarrhea~|~how often dizzy~|~how often nausea~|~illness (finding)~|~international metastatic renal cell carcinoma database consortium (imdc) criteria - poor-risk group~|~language proficiency - poor~|~loss of appetite (finding)~|~nausea subscale~|~nausea visual analogue scale~|~nausea, ctcae 3.0~|~nausea, ctcae 5.0~|~nausea:presence or threshold:point in time:^patient:ordinal~|~patient condition code - poor~|~poor - grade value~|~poor - qualifier~|~recent~|~skin turgor~|~specimen quality - poor~|~tachycardia by ecg finding~|~uncompensated~|~usual severity diarrhea~|~usual severity dizziness~|~usual severity nausea~|~weakness~|~and/or~|~bothered by vomiting~|~dry~|~dry skin~|~dryness (characteristic)~|~entity handling - dry~|~excessive exercise (finding)~|~have been vomiting~|~how much distress vomiting~|~how often vomiting~|~lengthened (qualifier value)~|~prolonged~|~prolonged release mechanism of action~|~special handling code - dry~|~usual severity vomiting~|~vomiting, ctcae
polyuria~|~tachycardia~|~abdominal pain~|~dehydration~|~tachypnea~|~polydipsia~|~hyperphagia~|~history~|~hypotension~|~concept history~|~dehydration procedure~|~dehydration, ctcae~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~hypotension, ctcae~|~in addition to~|~increased sweating~|~known~|~kussmaul's respiration~|~lrba gene~|~last~|~meal (occasion for eating)~|~medical history~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pharmaceutical preparations~|~presentation~|~symptomatic~|~tachycardia by ecg finding~|~with - dosing instruction fragment~|~new onset~|~abdominal pain, ctcae 5~|~abnormal mental state~|~dietary indiscretion~|~two hundred fifty~|~mg/dl
hunger~|~tremor~|~malnutrition~|~drug abuse~|~history~|~absent~|~abuse~|~concept history~|~excessive~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~hypothermia (central) (local)~|~hypothermia due to exposure~|~hypothermia, ctcae~|~hypothermia, natural~|~in addition to~|~increased sweating~|~known~|~lrba gene~|~meal (occasion for eating)~|~medical history~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pharmaceutical preparations~|~presentation~|~recent~|~symptomatic~|~victim of abuse finding~|~weakness~|~with - dosing instruction fragment~|~with intensity~|~new onset~|~abnormal mental state~|~insulin used~|~mg/dl
antipsychotic agents~|~tardive dyskinesia~|~muscle cramp~|~pain~|~spasm~|~human body~|~tongue~|~ingestion~|~phenothiazine~|~pharmaceutical preparations~|~recent~|~neck~|~protrusion~|~adult human body~|~body of stomach~|~body structure~|~change -- procedure~|~changed status~|~changing~|~delta (difference)~|~document body~|~drug-induced tardive dyskinesia~|~drugs - dental services~|~entire~|~entire neck~|~entire tongue~|~gaze~|~human body structure~|~increase~|~kantr gene~|~known~|~medications~|~muscle twitch~|~neck of pancreas~|~neck of urinary bladder~|~phenothiazine measurement~|~phenothiazine [epc]~|~residue on tongue~|~spatial displacement~|~whole~|~whole body~|~dendritic spine neck~|~dystonic reaction~|~facial muscle spasm~|~medication - hl7 publishing domain~|~abdominal rigidity~|~administration method - pain~|~adverse event associated with pain~|~definitely related to intervention~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~relate - vinyl resin~|~related personal status~|~relationships~|~role link type - related~|~twisted~|~usual severity pain~|~convoluted shape~|~fluphenazines
temperature~|~myalgia~|~abdominal pain~|~body temperature~|~erythema~|~communicable diseases~|~dysuria~|~headache~|~chest pain~|~flushing~|~symptoms~|~sore throat~|~chills~|~exanthema~|~adverse event associated with infection~|~associated symptom~|~chills, ctcae~|~cough frequency~|~cough, ctcae~|~coughing~|~dysuria, ctcae~|~eruptions~|~feels warm~|~have been coughing~|~headache, ctcae~|~how much distress cough~|~infection~|~like~|~myalgia, ctcae 5~|~red color~|~redness~|~rigor - temperature-associated observation~|~symptoms aspect~|~usual severity cough~|~weakness~|~around~|~sweaty~|~warming process~|~101 mouse~|~abdominal pain, ctcae 5~|~abnormal mental state~|~chest pain:finding:point in time:^patient:ordinal~|~rhinovirus serotype 101
epistaxis~|~renal hypertension~|~transient ischemic attack~|~cerebrovascular accident~|~dyspnea~|~seizures~|~diabetes mellitus~|~chest pain~|~transient cerebral ischemia~|~kidney failure~|~systolic pressure~|~disease~|~organ~|~mmhg~|~dysfunction~|~associated with~|~dysfunction - skin disorders~|~diabetes~|~diastolic blood pressure measurement~|~dyspnea, ctcae~|~eng gene~|~eng wt allele~|~end~|~endoglin, human~|~epistaxis, ctcae~|~etiology~|~etiology aspects~|~functional disorder~|~in addition to~|~including (qualifier)~|~medical~|~medical referral type~|~medical school type~|~medical service~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~organization administrative structures~|~organization and administration aspects~|~pharmaceutical preparations~|~science of etiology~|~seizure, ctcae 3.0~|~seizure, ctcae 5.0~|~stop (qualifier value)~|~stroke, ctcae~|~tacca leontopetaloides~|~with - dosing instruction fragment~|~end - actrelationshipcheckpoint~|~headache severe~|~hypertensive medication~|~physiopathological~|~120~|~220~|~and/or~|~chest pain:finding:point in time:^patient:ordinal~|~diastolic blood pressure~|~evidence of (contextual qualifier)~|~intravascular diastolic:pressure:point in time:arterial system:quantitative~|~intravascular systolic:pressure:point in time:arterial system:quantitative~|~nausea and vomiting~|~non-compliance~|~renal failure, ctcae~|~systolic blood pressure measurement
lethargy~|~tachycardia~|~ingestion~|~bradycardia~|~seizures~|~ablepharon-macrostomia syndrome~|~injection~|~alcohol consumption~|~andorra~|~hypotension~|~medications~|~pharmaceutical preparations~|~medication - hl7 publishing domain~|~illicit drugs~|~accelerator mass spectrometry~|~access~|~accident due to exposure to weather conditions~|~accidental ingestion~|~and~|~and - dosing instruction fragment~|~availability of~|~biological absorption~|~bradycardia by ecg finding~|~chemicals~|~data type - quantity~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~energy absorption~|~exposure domain~|~exposure to~|~hypertension, ctcae~|~hypertensive disease~|~hypotension, ctcae~|~inhalation dosing unit~|~inhalation method of administration~|~inhalation route of drug administration~|~injection dosing unit~|~injection method of administration~|~injection route of drug administration~|~injection of therapeutic agent~|~injection procedure~|~injury due to exposure to external cause~|~inspiration function~|~known~|~lethargy, ctcae~|~mdf attribute type - quantity~|~material absorption~|~numerous~|~pharmaceutical substances~|~pharmacokinetics: absorption~|~process of absorption~|~quantity~|~relationshipconjunction - and~|~role class - access~|~suspected diagnosis~|~suspected qualifier~|~twist2 wt allele~|~tachycardia by ecg finding~|~toxin~|~unresponsive to treatment~|~combative~|~intent~|~route of exposure~|~unresponsive behavior~|~victim~|~non mouse~|~negation~|~slow respiration~|~x-ray exposure time
seizures~|~lethargy~|~unconscious state~|~age of onset~|~oral cavity~|~back~|~craniocerebral trauma~|~tonic-clonic epilepsy~|~aura~|~clonic seizures~|~epilepsy~|~seizures, focal~|~back structure, excluding neck~|~back structure, including back of neck~|~dorsal~|~entire back (surface region)~|~trauma~|~aurka gene~|~aurka wt allele~|~bystander~|~count of entities~|~data type interval~|~decreased~|~decreasing~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~from~|~history of present illness~|~incontinence~|~interval~|~lucid~|~mdf attributetype - number~|~medical history~|~numbers~|~observed~|~onset of (contextual qualifier)~|~oral~|~oral (intended site)~|~oral dosage form~|~oral route of drug administration~|~parameterized data type - interval~|~past history of~|~post-ictal state~|~reduced~|~tonics~|~tongue biting~|~tonic - clonic seizures~|~trauma, nursing specialty~|~traumatic injury~|~wounds and injuries~|~new onset~|~seizure activity~|~trauma qualifier~|~abnormal mental state~|~visual changes
myalgia~|~vision~|~communicable diseases~|~tachycardia~|~acetaminophen~|~abdominal pain~|~erythema~|~hospitalization~|~sepsis~|~diabetes mellitus~|~hiv~|~dysuria~|~headache~|~ibuprofen~|~chest pain~|~transplantation~|~androgen binding protein~|~fever~|~flushing~|~malignant neoplasms~|~septicemia~|~sore throat~|~andorra~|~chills~|~exanthema~|~hypotension~|~adverse event associated with infection~|~infection~|~recent~|~immunocompromised host~|~transplant~|~acetaminophen assay~|~acetaminophen [epc]~|~and~|~and - dosing instruction fragment~|~associated symptom~|~bedridden~|~cchcr1 wt allele~|~cancer genus~|~cancer:-:point in time:^patient:-~|~chemotherapeutic perfusion~|~chills, ctcae~|~cough frequency~|~cough, ctcae~|~coughing~|~decreased~|~decreasing~|~diabetes~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~dysuria, ctcae~|~eruptions~|~facilitated oscillatory release technique~|~feels warm~|~fix~|~flu like symptoms, ctcae~|~hiv vaccine~|~have been coughing~|~headache, ctcae~|~history of present illness~|~how much distress cough~|~human immunodeficiency virus measurement~|~hypotension, ctcae~|~immobile~|~influenza-like symptoms~|~intake~|~last~|~medical history~|~myalgia, ctcae 5~|~past history of~|~perfusion (biological)~|~perfusion (procedure)~|~perfusion route~|~preposition for~|~primary malignant neoplasm~|~red color~|~redness~|~reduced~|~relationshipconjunction - and~|~rigor - temperature-associated observation~|~shbg wt allele~|~sepsis (invertebrate)~|~sepsis, ctcae~|~severities~|~source~|~source (property) (qualifier value)~|~specialty type - cancer~|~systolic blood pressure measurement~|~tachycardia by ecg finding~|~term source~|~usual severity cough~|~wwox gene~|~wwox wt allele~|~weakness~|~with intensity~|~around~|~mmhg~|~sweaty~|~warming process~|~abdominal pain, ctcae 5~|~abnormal mental state~|~chest pain:finding:point in time:^patient:ordinal~|~evidence of (contextual qualifier)~|~injury wounds~|~route of administration - wound~|~specimen source codes - wound~|~specimen type - wound~|~transplanted tissue~|~traumatic injury
cerebellar ataxia~|~aphasia~|~coronary artery disease~|~blindness~|~transient ischemic attack~|~ataxia~|~cerebrovascular accident~|~blood pressure~|~atrial fibrillation~|~computer assisted diagnosis~|~blood pressure determination~|~seizures~|~diabetes mellitus~|~anticoagulants~|~headache~|~dffb protein, human~|~dysphasia~|~facial paresis~|~sensory deprivation~|~transient cerebral ischemia~|~vomiting~|~disease~|~act relationship subset - previous~|~hypertension, ctcae~|~hypertensive disease~|~previous~|~mmhg~|~blood vessel~|~trauma~|~120~|~acod1 gene~|~acute ill-defined cerebrovascular disease~|~adverse event associated with vascular~|~associated with~|~ataxia as late effect of cerebrovascular disease~|~ataxia, ctcae 5.0~|~atrial fibrillation by ecg finding~|~atrial fibrillation, ctcae~|~b4galnt2 gene~|~cad gene~|~cald1 wt allele~|~caddo language~|~cardiac surgery procedures~|~collision-induced dissociation~|~dffb gene~|~dffb wt allele~|~diabetes~|~discipline of heart surgery~|~dysphasia, ctcae~|~ever told you have or had atrial fibrillation:finding:point in time:^patient:ordinal~|~fibrovascular~|~generalized~|~global~|~headache, ctcae~|~history of present illness~|~loss~|~medical history~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~past history of~|~pharmaceutical preparations~|~tacca leontopetaloides~|~trauma, nursing specialty~|~traumatic injury~|~unilateral~|~vascular~|~wounds and injuries~|~cyclophosphamide/dacarbazine/doxorubicin protocol~|~cyclophosphamide/doxorubicin/vincristine protocol~|~cytarabine/daunorubicin protocol~|~trauma qualifier~|~220~|~abnormal mental state~|~blood pressure finding~|~bothered by vomiting~|~diastolic blood pressure~|~diastolic blood pressure measurement~|~have been vomiting~|~how much distress vomiting~|~how often vomiting~|~intravascular diastolic:pressure:point in time:arterial system:quantitative~|~systemic arterial pressure~|~time of onset~|~usual severity vomiting~|~visual disturbance~|~vomiting, ctcae~|~paralysis/weakness~|~vertigo/dizziness
cerebellar ataxia~|~aphasia~|~coronary artery disease~|~blindness~|~transient ischemic attack~|~ataxia~|~cerebrovascular accident~|~blood pressure~|~atrial fibrillation~|~computer assisted diagnosis~|~blood pressure determination~|~seizures~|~diabetes mellitus~|~anticoagulants~|~headache~|~dffb protein, human~|~dysphasia~|~facial paresis~|~sensory deprivation~|~transient cerebral ischemia~|~vomiting~|~disease~|~act relationship subset - previous~|~hypertension, ctcae~|~hypertensive disease~|~previous~|~mmhg~|~blood vessel~|~trauma~|~120~|~acod1 gene~|~acute ill-defined cerebrovascular disease~|~adverse event associated with vascular~|~associated with~|~ataxia as late effect of cerebrovascular disease~|~ataxia, ctcae 5.0~|~atrial fibrillation by ecg finding~|~atrial fibrillation, ctcae~|~b4galnt2 gene~|~cad gene~|~cald1 wt allele~|~caddo language~|~cardiac surgery procedures~|~collision-induced dissociation~|~dffb gene~|~dffb wt allele~|~diabetes~|~discipline of heart surgery~|~dysphasia, ctcae~|~ever told you have or had atrial fibrillation:finding:point in time:^patient:ordinal~|~fibrovascular~|~generalized~|~global~|~headache, ctcae~|~history of present illness~|~loss~|~medical history~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~past history of~|~pharmaceutical preparations~|~tacca leontopetaloides~|~trauma, nursing specialty~|~traumatic injury~|~unilateral~|~vascular~|~wounds and injuries~|~cyclophosphamide/dacarbazine/doxorubicin protocol~|~cyclophosphamide/doxorubicin/vincristine protocol~|~cytarabine/daunorubicin protocol~|~trauma qualifier~|~220~|~abnormal mental state~|~blood pressure finding~|~bothered by vomiting~|~diastolic blood pressure~|~diastolic blood pressure measurement~|~have been vomiting~|~how much distress vomiting~|~how often vomiting~|~intravascular diastolic:pressure:point in time:arterial system:quantitative~|~systemic arterial pressure~|~time of onset~|~usual severity vomiting~|~visual disturbance~|~vomiting, ctcae~|~paralysis/weakness~|~vertigo/dizziness
diastole~|~pregnancy~|~physical activity~|~seizures~|~birth~|~headache~|~ablepharon-macrostomia syndrome~|~androgen binding protein~|~childbirth~|~symptoms~|~uterus~|~females~|~greater~|~in addition to~|~with - dosing instruction fragment~|~equal~|~relational operator - equal~|~obstetric delivery~|~postpartum period~|~mmhg~|~week~|~woman~|~accelerator mass spectrometry~|~active~|~activities~|~activity (animal life circumstance)~|~birth of child~|~cchcr1 wt allele~|~fda establishment activity terminology~|~headache, ctcae~|~hypertension, ctcae~|~hypertensive disease~|~known~|~like~|~more~|~numerous~|~patient currently pregnant~|~persistent~|~persistent embryonic structure~|~physical activity measurement~|~recent~|~shbg wt allele~|~seizure, ctcae 3.0~|~seizure, ctcae 5.0~|~suspected diagnosis~|~suspected qualifier~|~symptoms aspect~|~systolic blood pressure measurement~|~twist2 wt allele~|~up~|~1 (finding)~|~140~|~and/or~|~during values~|~female phenotype~|~female, self-report~|~nausea and vomiting~|~one~|~peripheral edema
diastole~|~pregnancy~|~seizures~|~birth~|~androgen binding protein~|~childbirth~|~uterus~|~females~|~greater~|~equal~|~relational operator - equal~|~obstetric delivery~|~postpartum period~|~in addition to~|~recent~|~with - dosing instruction fragment~|~mmhg~|~week~|~woman~|~birth of child~|~cchcr1 wt allele~|~hypertension, ctcae~|~hypertensive disease~|~known~|~patient currently pregnant~|~persistent~|~persistent embryonic structure~|~shbg wt allele~|~seizure, ctcae 3.0~|~seizure, ctcae 5.0~|~suspected diagnosis~|~suspected qualifier~|~systolic blood pressure measurement~|~up~|~140~|~active~|~active control~|~active license~|~active state~|~active study~|~active brand of pseudoephedrine-triprolidine~|~and/or~|~concept status - active~|~document storage - active~|~document storage status - active~|~during values~|~editstatus - active~|~entity status - active~|~female phenotype~|~female, self-report~|~immunization registry status - active~|~managed participation status - active~|~role status - active~|~active (hl7 rolelink)
tachycardia~|~androgen binding protein~|~hypotension~|~cchcr1 wt allele~|~chemotherapeutic perfusion~|~decreased~|~decreasing~|~hypotension, ctcae~|~perfusion (biological)~|~perfusion (procedure)~|~perfusion route~|~reduced~|~shbg wt allele~|~systolic blood pressure measurement~|~tachycardia by ecg finding~|~mmhg~|~abnormal mental state
infant, newborn~|~infant~|~less than~|~old~|~old episode~|~participation type - baby~|~viable~|~12 hours~|~neonatal (qualifier value)~|~newborn (finding)~|~newborn encounter admission source
blood~|~muscle cramp~|~pain~|~menstruation~|~back~|~abdomen~|~back structure, excluding neck~|~back structure, including back of neck~|~body tissue~|~cramping sensation quality~|~dorsal~|~entire back (surface region)~|~in blood~|~in addition to~|~intrauterine pregnancy~|~known~|~suspected diagnosis~|~suspected qualifier~|~tissue specimen code~|~with - dosing instruction fragment~|~peripheral blood~|~abdominal (qualifier value)~|~administration method - pain~|~adverse event associated with pain~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~non mouse~|~negation~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~usual severity pain~|~vaginal hemorrhage~|~vaginal hemorrhage, ctcae
dyspnea~|~hemoptysis~|~respiratory sounds~|~work of breathing~|~tachypnea~|~negative surgical margin~|~rales~|~rhonchi~|~stridor~|~wheezing~|~history~|~thoracic injuries~|~absent~|~accessory skeletal muscle~|~accident due to exposure to weather conditions~|~basilar rales~|~clear~|~concept history~|~cough frequency~|~cough, ctcae~|~coughing~|~decreased~|~decreasing~|~dyspnea, ctcae~|~epidermal cgvhd score 0~|~etiology~|~etiology aspects~|~event seriousness - significant~|~exposure domain~|~exposure to~|~have been coughing~|~have shortness of breath question~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~how much distress cough~|~how much distress shortness of breath~|~how often shortness of breath~|~injury due to exposure to external cause~|~medical history~|~pharyngeal stripping wave absent~|~pursed lips~|~recent~|~reduced~|~remote control command - clear~|~science of etiology~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~significant~|~specimen source codes - respiratory~|~statistical significance~|~stridor, ctcae~|~toxic~|~toxic effect~|~tripod position~|~usual severity cough~|~usual severity shortness of breath~|~without~|~new onset~|~respiratory~|~abnormal breath sounds~|~possible~|~possible diagnosis~|~possibly related to intervention~|~usage~|~use - dosing instruction imperative~|~wheezing, ctcae~|~utilization qualifier
air~|~angiotensin-converting enzyme inhibitors~|~airway obstruction~|~cyanosis~|~recent~|~angiotensin-converting enzyme inhibitor (disposition)~|~cdisc events class~|~cdisc sdtm anatomical location terminology~|~cyanosis, ctcae~|~decreased~|~decreasing~|~event~|~event unit~|~exchange (clinical)~|~inadequate (qualifier)~|~level of consciousness~|~location~|~partial~|~reduced~|~target awareness - partial~|~unsatisfactory~|~angiotensin-converting enzyme inhibitor activity~|~degree of relationship - exchange~|~foreign body aspiration~|~acute insulin response~|~ai/rheum~|~airn gene~|~air (substance)~|~complete~|~complete pharyngeal contraction~|~completion status for valid values - complete~|~data operation - complete~|~finish - dosing instruction imperative~|~secondary to~|~usage~|~use - dosing instruction imperative~|~utilization qualifier
bronchitis, chronic~|~continuous positive airway pressure~|~work of breathing~|~dyspnea~|~tachypnea~|~chronic obstructive airway disease~|~lymphoid interstitial pneumonia~|~rhonchi~|~stridor~|~wheezing~|~allergens~|~andorra~|~smoke~|~respiration~|~chronic obstructive pulmonary disease of horses~|~allergens identified:presence or identity:point in time:serum:nominal~|~arcn1 gene~|~ability to speak~|~accessory skeletal muscle~|~address type - home~|~administration procedure~|~and~|~and - dosing instruction fragment~|~at home~|~biomaterial treatment~|~cenpj gene~|~chemicals~|~decreased~|~decreasing~|~entire lip~|~exertion~|~expiration, function~|~exposure to~|~gdc lymphatic invasion present terminology~|~h/o: asthma~|~have shortness of breath question~|~home environment~|~home oxygen supply~|~how much distress shortness of breath~|~how often shortness of breath~|~lip structure~|~machine~|~medical device emits smoke~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~organization unit type - home~|~person location type - home~|~pharmaceutical preparations~|~phase~|~reduced~|~relationshipconjunction - and~|~smg1 gene~|~smg1 wt allele~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~stridor, ctcae~|~therapeutic procedure~|~tobacco smoke~|~treating~|~treatment epoch~|~treatment study~|~trial phase~|~usual severity shortness of breath~|~visit user code - home~|~home health encounter~|~therapeutic aspects~|~treatment - actinformationmanagementreason~|~breathing distress question~|~inspiration function~|~lengthened (qualifier value)~|~prolonged~|~prolonged release mechanism of action~|~reactive airway disease~|~usage~|~use - dosing instruction imperative~|~wheezing, ctcae~|~respiratory gaseous exchange in organisms~|~utilization qualifier
bronchiolitis obliterans organizing pneumonia~|~bronchitis, chronic~|~continuous positive airway pressure~|~work of breathing~|~dyspnea~|~tachypnea~|~pulmonary emphysema~|~lymphoid interstitial pneumonia~|~police officer~|~rhonchi~|~stridor~|~creatinol phosphate~|~wheezing~|~andorra~|~respiration~|~ability to speak~|~accessory skeletal muscle~|~address type - home~|~administration procedure~|~and~|~and - dosing instruction fragment~|~at home~|~biomaterial treatment~|~card16 gene~|~cenpj gene~|~decreased~|~decreasing~|~entire lip~|~exertion~|~expiration, function~|~gdc lymphatic invasion present terminology~|~have shortness of breath question~|~history of present illness~|~home environment~|~home oxygen supply~|~how much distress shortness of breath~|~how often shortness of breath~|~lip structure~|~machine~|~medical history~|~organization unit type - home~|~past history of~|~pathological accumulation of air in tissues~|~person location type - home~|~phase~|~reduced~|~relationshipconjunction - and~|~smg1 gene~|~smg1 wt allele~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~stridor, ctcae~|~therapeutic procedure~|~treating~|~treatment epoch~|~treatment study~|~trial phase~|~usual severity shortness of breath~|~visit user code - home~|~cyclophosphamide/prednisolone/vincristine protocol~|~cyclophosphamide/prednisone/vincristine protocol~|~home health encounter~|~therapeutic aspects~|~treatment - actinformationmanagementreason~|~breathing distress question~|~inspiration function~|~lengthened (qualifier value)~|~prolonged~|~prolonged release mechanism of action~|~usage~|~use - dosing instruction imperative~|~wheezing, ctcae~|~respiratory gaseous exchange in organisms~|~utilization qualifier
pneumonia~|~myalgia~|~abdominal pain~|~dyspnea~|~communicable diseases~|~dysuria~|~headache~|~chest pain~|~rales~|~rhonchi~|~fever~|~sore throat~|~wheezing~|~exanthema~|~hospitals~|~respiration~|~illness (finding)~|~recent~|~specimen source codes - respiratory~|~respiratory~|~acquired (qualifier value)~|~acquired name~|~adverse event associated with infection~|~associated symptom~|~at risk for aspiration~|~basilar rales~|~cough frequency~|~cough, ctcae~|~coughing~|~dysuria, ctcae~|~eruptions~|~facilitated oscillatory release technique~|~flu like symptoms, ctcae~|~gradual onset~|~h/o: bronchitis~|~have been coughing~|~have shortness of breath question~|~headache, ctcae~|~hospital environment~|~how much distress cough~|~how much distress shortness of breath~|~how often shortness of breath~|~in addition to~|~infection~|~influenza-like symptoms~|~last~|~localized~|~month of may~|~myalgia, ctcae 5~|~not required~|~not required - hl7conformanceinclusion~|~organization unit type - hospital~|~preposition for~|~present~|~presentation~|~productive cough~|~productive cough, ctcae~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~upper~|~usual severity cough~|~usual severity shortness of breath~|~wwox gene~|~wwox wt allele~|~with - dosing instruction fragment~|~within~|~day~|~hospital visit~|~abdominal pain, ctcae 5~|~chest pain on breathing~|~chest pain:finding:point in time:^patient:ordinal~|~fever symptoms (finding)~|~fever, ctcae~|~wheezing, ctcae
dyspnea~|~rales~|~pulmonary edema~|~basilar rales~|~bilateral~|~cdisc findings class~|~dyspnea, ctcae~|~in addition to~|~procedure findings:finding:point in time:^patient:narrative~|~pulmonary edema, ctcae~|~with - dosing instruction fragment~|~findings aspects
risk~|~syncope~|~tachycardia~|~hemoptysis~|~respiratory sounds~|~dyspnea~|~chest pain~|~recent~|~blood clot~|~embolism~|~embolus~|~negative surgical margin~|~ocular cicatricial pemphigoid~|~thrombosis~|~immobilization~|~travel~|~administration occupational activities~|~administration procedure~|~agent administration~|~clear~|~dyspnea, ctcae~|~epidermal cgvhd score 0~|~fbl gene~|~general surgery specialty~|~immobilization test~|~increase~|~jugular venous engorgement~|~level of care - surgery~|~limb structure~|~month of may~|~operative surgical procedures~|~remote control command - clear~|~subject risk~|~sudden onset (attribute)~|~sudden onset (contextual qualifier) (qualifier value)~|~surgery specialty~|~surgical aspects~|~syncope (amphibian)~|~syncope, ctcae 5.0~|~tachycardia by ecg finding~|~thrombosis of blood vessel~|~travel charge~|~chest pain:finding:point in time:^patient:ordinal~|~chest swelling~|~within 30 days~|~unilateral leg pain
comorbidity~|~chronic obstructive airway disease~|~anemia~|~body part~|~severing~|~traumatic injury~|~laceration~|~time~|~arcn1 gene~|~anemia, ctcae~|~chronic obstructive pulmonary disease of horses~|~complete~|~complete agreement~|~completely - dosing instruction fragment~|~completely able~|~contamination~|~crushing procedure~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~genus anemia~|~mechanism of injury~|~medical~|~medical device contamination during use~|~medical referral type~|~medical school type~|~medical service~|~penetration~|~specimen reject reason - contamination~|~traumatic and/or non-traumatic injury~|~adulteration~|~data types - time~|~injury wounds~|~route of administration - wound~|~specimen source codes - wound~|~specimen type - wound~|~time (foundation metadata concept)~|~value type - time
hoarseness~|~pain~|~unconscious state~|~electricity~|~bulla~|~wheezing~|~hypotension~|~shock~|~burns, inhalation~|~edema~|~contact with~|~direct (qualifier)~|~direct - postaladdressuse~|~direct type of relationship~|~lightning (phenomenon)~|~private communication address~|~source~|~source (property) (qualifier value)~|~term source~|~traumatic injury~|~chemical reaction~|~heat (physical force)~|~trauma~|~time~|~additional~|~from~|~hoarseness, ctcae~|~hypotension, ctcae~|~respiratory distress~|~tissue injury~|~trauma, nursing specialty~|~traumatic and/or non-traumatic injury~|~wounds and injuries~|~trauma qualifier~|~administration method - pain~|~adverse event associated with pain~|~blistering eruption~|~burn injury~|~data types - time~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~potential~|~swelling~|~time (foundation metadata concept)~|~usual severity pain~|~value type - time~|~wheezing, ctcae
pain~|~organ~|~hemorrhage~|~traumatic injury~|~trauma~|~act relationship checkpoint - through~|~causing~|~evisceration - action~|~through~|~trauma, nursing specialty~|~wounds and injuries~|~protrusion~|~trauma qualifier~|~administration method - pain~|~adverse event associated with pain~|~code system type - internal~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~injury wounds~|~internal~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~route of administration - wound~|~specimen source codes - wound~|~specimen type - wound~|~usual severity pain
eye~|~aids related complex~|~low vision~|~eye injuries~|~eye pain~|~pain~|~entire eye~|~corneal abrasions~|~visual impairment~|~xerostomia~|~andorra~|~chemical burns~|~in addition to~|~traumatic injury~|~with - dosing instruction fragment~|~foreign bodies~|~laceration~|~trauma~|~abnormal vision~|~and~|~and - dosing instruction fragment~|~avulsed wound~|~bed status - closed~|~closed~|~excessive tearing~|~eye specimen~|~eye specimen source code~|~foreign body (physical object)~|~have excessive tearing~|~including (qualifier)~|~orbital region~|~relationshipconjunction - and~|~resulting in~|~spray (action)~|~spray (administration method)~|~spray dosage form~|~spray dosing unit~|~spraying behavior~|~trauma, nursing specialty~|~traumatic and/or non-traumatic injury~|~unspecified visual loss~|~wounds and injuries~|~etiology unknown~|~nasal drainage~|~trauma qualifier~|~apoptosis repressor with card domain~|~arc gene~|~administration method - pain~|~adverse event associated with pain~|~arcuate shape~|~atypical reparative cell~|~burn injury~|~burning sensation~|~burning sensation quality~|~eye pain, ctcae 3.0~|~eye pain, ctcae 5.0~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~nol3 gene~|~open~|~open surgical procedure~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~radiation arc~|~smoking method of administration~|~usual severity pain
brain concussion~|~traumatic brain injury~|~pain~|~unconscious state~|~seizures~|~craniocerebral trauma~|~whole-body irradiation~|~convulsions~|~depressed level of consciousness~|~gclc protein, human~|~vomiting~|~edema~|~hemorrhage~|~trauma~|~time~|~blunt (object)~|~blunted~|~ceramide glucosyltransferase, human~|~device plate~|~etiology~|~etiology aspects~|~failure~|~failure (biologic function)~|~gclc gene~|~gclc wt allele~|~history of present illness~|~mechanism of injury~|~medical history~|~operative surgical procedures~|~past history of~|~penetration~|~personal failure~|~respiratory distress~|~resulting in~|~science of etiology~|~stent, device~|~surgical service~|~trauma, nursing specialty~|~traumatic injury~|~ugcg gene~|~ugcg wt allele~|~wounds and injuries~|~trauma qualifier~|~abnormal mental state~|~administration method - pain~|~adverse event associated with pain~|~bothered by vomiting~|~data types - time~|~feel pain~|~frequency of pain question~|~have been vomiting~|~have pain~|~how much distress pain~|~how much distress vomiting~|~how often vomiting~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~posturing~|~swelling~|~time (foundation metadata concept)~|~usual severity pain~|~usual severity vomiting~|~value type - time~|~vomiting, ctcae
unconscious state~|~ablepharon-macrostomia syndrome~|~abdominal cavity~|~abdomen~|~chest~|~hypotension~|~pelvis~|~shock~|~traumatic injury~|~abdominopelvic structure~|~accelerator mass spectrometry~|~anterior thoracic region~|~associated with~|~body tissue~|~damage~|~drug vehicle~|~entire abdomen~|~entire pelvis~|~female genital injuries~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~hypotension, ctcae~|~magee1 gene~|~male genital injuries~|~mechanism of injury~|~musculoskeletal~|~musculoskeletal:-:point in time:^patient:-~|~numerous~|~pelvic cavity structure~|~short stature, onychodysplasia, facial dysmorphism, and hypotrichosis syndrome~|~soft~|~twist2 wt allele~|~tissue specimen code~|~tissue damage~|~traumatic and/or non-traumatic injury~|~vehicle (transportation)~|~trauma qualifier~|~urologic injuries~|~unconscious personality factor
pain~|~movement~|~palpation~|~3,5-dichloro-1,4-aminophenol~|~blood circulation~|~fractures, closed~|~traumatic and/or non-traumatic injury~|~traumatic injury~|~time~|~absent~|~act relationship subset - previous~|~affected area of body~|~affected site~|~arrival - action~|~circulatory process~|~decreased~|~decreasing~|~device motor~|~esthesia~|~from~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~mechanism of injury~|~observation of sensation~|~pharyngeal stripping wave absent~|~previous~|~recent injury~|~reduced~|~sensation quality~|~arrival - actrelationshiptype~|~motor movement~|~administration method - pain~|~adverse event associated with pain~|~and/or~|~data types - time~|~distal (qualifier value)~|~distal resection margin~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~open~|~open surgical procedure~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~time (foundation metadata concept)~|~usual severity pain~|~value type - time
foreign bodies~|~ballistics~|~foreign body (physical object)~|~penetration~|~consider~|~wounds, penetrating~|~act relationship checkpoint - exit~|~any~|~any data type~|~body part~|~computer programming object~|~embedding~|~entrance~|~evaluation and management note:finding:point in time:{setting}:document:{provider}~|~exit~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~mechanism of injury~|~note (document)~|~object class~|~physical object~|~toxin~|~and/or~|~injury wounds~|~wounds - qualifier
pain~|~amnesia~|~gamma rays~|~cicatrix~|~flunitrazepam~|~ketamine~|~4-butyrolactone~|~ethanol~|~dental occlusion~|~4-hydroxybutyric acid~|~hydroxybutyric acids~|~memory loss~|~rohypnol~|~gamma hydroxybutyrate~|~contusions~|~defecation~|~urination~|~edema~|~administration method - pain~|~adverse event associated with pain~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~usual severity pain~|~alcohols~|~genital system~|~genitalia~|~academic research enhancement awards~|~alcohol - recreational drug use code~|~area~|~aspects of signs~|~assault~|~disturbance in mood~|~drugs - dental services~|~ethanol measurement~|~exposure to~|~flunitrazepam measurement~|~gamma - unit of measure~|~geographic locations~|~greek letter gamma~|~in addition to~|~mlst8 gene~|~manufactured sign~|~massive~|~pharmaceutical preparations~|~recent~|~rectal (intended site)~|~rectal dosage form~|~rectal route of drug administration~|~regulatory report~|~report (document)~|~report:finding:point in time:{setting}:document:{role}~|~reporting~|~scar tissue~|~specimen source codes - genital~|~specimen type - genital~|~tube,rectal,24fr,plastic b#6510~|~traumatic and/or non-traumatic injury~|~traumatic injury~|~unexplained~|~with - dosing instruction fragment~|~date rape~|~rectal~|~bite (event)~|~cep70 gene~|~genital hemorrhage~|~physical findings~|~possible~|~possible diagnosis~|~possibly related to intervention~|~sexual assault~|~specimen source codes - bite~|~swelling~|~bite injury
numbness~|~andorra~|~hypotension~|~paralysed~|~nervous system physiological phenomena~|~and~|~and - dosing instruction fragment~|~decreased~|~decreasing~|~deferred~|~delayed release mechanism of action~|~delayed testing~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~hypotension, ctcae~|~inferior~|~mechanism of injury~|~neurologic (qualifier value)~|~neurological:-:point in time:^patient:-~|~present~|~reduced~|~relationshipconjunction - and~|~site of~|~table frame - below~|~traumatic and/or non-traumatic injury~|~traumatic injury~|~views delayed~|~compromise~|~elapsed time~|~time since injury
patient discharge~|~delirium~|~cardiac arrhythmia~|~taser~|~congenital abnormality~|~heart diseases~|~patients~|~chemical probe~|~dna probe method~|~delirium, ctcae~|~disabled person code - patient~|~embedding~|~facilitated oscillatory release technique~|~mail claim party - patient~|~preposition for~|~probe brand of methazole herbicide~|~probes~|~relationship modifier - patient~|~report source - patient~|~specimen source codes - patient~|~specimen type - patient~|~veterinary patient~|~wwox gene~|~wwox wt allele~|~probe gene fragment~|~teratologic~|~body fluid discharge~|~discharge, body substance, sample~|~discharge, body substance~|~excitation~|~excited~|~specimen source codes - discharge~|~usage~|~use - dosing instruction imperative~|~utilization qualifier
apnea~|~trauma qualifier~|~trauma~|~traumatic injury~|~trauma, nursing specialty~|~wounds and injuries~|~absent pulse~|~acute - triage code~|~admission level of care code - acute~|~agonal respiration~|~any~|~any data type~|~apnea, ctcae~|~blunt (object)~|~blunted~|~etiology~|~etiology aspects~|~female genital injuries~|~male genital injuries~|~operative surgical procedures~|~penetration~|~present~|~problem~|~problem:find:pt:^patient:nom~|~rhythm~|~science of etiology~|~surgical service~|~traumatic~|~acute~|~acute inpatient encounter~|~rhythmic process (biological)~|~urologic injuries~|~evidence of (contextual qualifier)~|~non mouse~|~negation
unconscious state~|~apnea~|~cardiac arrest~|~pisum sativum~|~pulse rate~|~phosphoethanolamine~|~absent pulse~|~agonal respiration~|~apnea, ctcae~|~arrested progression~|~asystole by ecg finding~|~asystole, ctcae 3.0~|~asystole, ctcae 5.0~|~before~|~cdisc events class~|~confirmation~|~confirmed by~|~electrical activity of brain~|~electromechanical dissociation~|~encounter due to problems related to other legal circumstances - arrest~|~estimated~|~event~|~event unit~|~law enforcement arrest~|~leading~|~leads (device)~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~organized~|~pea preparation~|~peas - dietary~|~pharmaceutical preparations~|~physiologic pulse~|~pisum sativum (pea) extract~|~pulse phenomenon~|~pulse taking~|~rhythm~|~two or more~|~without~|~pea allergenic extract~|~rhythmic process (biological)~|~unconscious personality factor
calcium channel blockers~|~digoxin~|~breast feeding~|~adrenergic beta-antagonists~|~syncope~|~poverty~|~age of onset~|~apnea~|~seizures~|~clonidine~|~chest pain~|~ablepharon-macrostomia syndrome~|~infant, newborn~|~systolic pressure~|~child~|~cyanosis~|~infant~|~bilateral prophylactic mastectomy~|~hypoperfusion~|~in addition to~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pharmaceutical preparations~|~with - dosing instruction fragment~|~beats per minute~|~breaths per minute~|~heart diseases~|~trauma~|~accelerator mass spectrometry~|~apnea, ctcae~|~before~|~cdisc events class~|~calcium channel antagonists [moa]~|~child relation~|~cyanosis, ctcae~|~digoxin measurement~|~event~|~event unit~|~international metastatic renal cell carcinoma database consortium (imdc) criteria - poor-risk group~|~known~|~language proficiency - poor~|~maternal~|~maternal relative~|~mother (person)~|~newborn (finding)~|~offspring~|~onset of (contextual qualifier)~|~patient condition code - poor~|~poor - grade value~|~poor - qualifier~|~relationship - child~|~respiratory distress~|~seizure, ctcae 3.0~|~seizure, ctcae 5.0~|~specimen quality - poor~|~syncope (amphibian)~|~syncope, ctcae 5.0~|~twist2 wt allele~|~trauma, nursing specialty~|~traumatic injury~|~wounds and injuries~|~cholinergic~|~mmhg~|~trauma qualifier~|~abnormal mental state~|~age~|~age:time:point in time:^patient:quantitative~|~breastfeeding (infant)~|~breastfeeding (mother)~|~capillary filling, function (observable entity)~|~chest pain on breathing~|~chest pain:finding:point in time:^patient:ordinal~|~mottling
tachycardia~|~melena~|~systole~|~bradycardia~|~sepsis~|~communicable diseases~|~ablepharon-macrostomia syndrome~|~congestive heart failure~|~petechiae~|~septicemia~|~upper respiratory infections~|~fever~|~pallor~|~allergens~|~exanthema~|~hemorrhage~|~hypotension~|~recent~|~traumatic injury~|~fever symptoms (finding)~|~trauma~|~accelerator mass spectrometry~|~act relationship subset - previous~|~actual blood loss~|~adverse event associated with infection~|~allergen (brand of diphenylpyraline)~|~blood loss~|~bloody~|~bradycardia by ecg finding~|~choroidal fissure~|~clammy skin~|~coffee ground vomiting~|~cool - action~|~deferred~|~delayed release mechanism of action~|~delayed testing~|~eruptions~|~etiology~|~etiology aspects~|~exposure to~|~general surgery specialty~|~have you felt weak (question)~|~hemorrhagic~|~history of present illness~|~hypotension, ctcae~|~induce (action)~|~infection~|~level of care - surgery~|~medical~|~medical history~|~medical referral type~|~medical school type~|~medical service~|~operative surgical procedures~|~past history of~|~petechiae of skin~|~previous~|~science of etiology~|~sepsis (invertebrate)~|~sepsis, ctcae~|~specimen condition - cool~|~surgery specialty~|~surgical aspects~|~twist2 wt allele~|~tachycardia by ecg finding~|~trauma, nursing specialty~|~uri1 gene~|~uri1 wt allele~|~uniform resource identifier~|~views delayed~|~vomit contains coffee grounds finding~|~weak~|~weakness~|~wounds and injuries~|~mmhg~|~trauma qualifier~|~uti symptoms~|~african american~|~african race~|~age~|~age:time:point in time:^patient:quantitative~|~aspects of signs~|~black - structured product labeling color~|~black color~|~black race~|~capillary filling, function (observable entity)~|~feces color: tarry~|~fever, ctcae~|~injury wounds~|~manufactured sign~|~no evidence of~|~pale color~|~pale color saturation~|~patient observed to be pale~|~physical findings~|~route of administration - wound~|~specimen source codes - wound~|~specimen type - wound
marfan syndrome~|~armenia~|~pain~|~hypesthesia~|~numbness~|~jaw~|~shoulder~|~upper arm~|~upper extremity~|~neck~|~sequence arm~|~akr1a1 wt allele~|~aldose reductase m gene~|~armc9 gene~|~activities~|~axillary reverse mapping~|~cdisc events class~|~chest discomfort~|~either~|~entire jaw region~|~entire neck~|~entire shoulder region~|~entire upper arm~|~entire upper limb~|~epigastric discomfort~|~epigastric fullness~|~event~|~event unit~|~focal~|~including (qualifier)~|~jaw device~|~neck of pancreas~|~neck of urinary bladder~|~palpitations~|~palpitations, ctcae~|~protocol treatment arm~|~recent~|~rhythm~|~upper back structure~|~weakness~|~dendritic spine neck~|~rhythmic process (biological)~|~abnormal vital signs~|~administration method - pain~|~adverse event associated with pain~|~amount type - rate~|~baresthesia~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain radiation:finding:point in time:*:nominal~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain radiation~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~pressure (finding)~|~pressure (property)~|~pressure - action~|~pressure- physical agent~|~rate~|~rating (action)~|~usual severity pain
cold temperature~|~temperature~|~apnea~|~body temperature~|~ethanol~|~barbiturates~|~environment~|~submersion~|~absent pulse~|~alcohols~|~immersion~|~viral nucleocapsid location~|~agonal respiration~|~alcohol - recreational drug use code~|~any~|~any data type~|~apnea, ctcae~|~barbiturates measurement~|~core~|~core device~|~core specimen~|~electrocardiogram finding~|~environmental~|~ethanol measurement~|~etiology~|~etiology aspects~|~exposure to~|~hypothermia (central) (local)~|~hypothermia due to exposure~|~hypothermia, ctcae~|~hypothermia, natural~|~immersion investigative technique~|~immersion route of exposure~|~medical~|~medical referral type~|~medical school type~|~medical service~|~poisoning by, adverse effect of and underdosing of barbiturates~|~processor core~|~rhythm~|~science of etiology~|~drug ingestion~|~rhythmic process (biological)~|~evidence of (contextual qualifier)
adenosine~|~digoxin~|~supraventricular tachycardia~|~wolff-parkinson-white syndrome~|~dyspnea~|~syncope~|~vertigo~|~energy drinks~|~dizziness~|~chest pain~|~diet therapy~|~androgen binding protein~|~decongestants~|~ingestion~|~irritable mood~|~thyroid (usp)~|~diet~|~vomiting~|~cardiomyopathies~|~child~|~infant~|~pulmonary edema~|~shock~|~thyroid gland~|~history of present illness~|~medical history~|~medications~|~month of may~|~past history of~|~thyroid diseases~|~systolic blood pressure measurement~|~before~|~cchcr1 wt allele~|~cardiac flutter~|~congenital heart disease~|~digoxin measurement~|~dizziness, ctcae 3.0~|~dizziness, ctcae 5.0~|~electrocardiogram finding~|~fbl gene~|~flutter (respiratory device)~|~have~|~have dizziness~|~how much distress dizziness~|~how often dizzy~|~include (action)~|~including (qualifier)~|~increased sweating~|~irritability, ctcae~|~irritation - emotion~|~late~|~late stage~|~microcephaly, epilepsy, and diabetes syndrome~|~offspring~|~palpitations~|~palpitations, ctcae~|~pharmaceutical preparations~|~pills~|~possess~|~prior medication usage~|~pulmonary edema, ctcae~|~shbg wt allele~|~supraventricular tachycardia by ecg finding~|~syncope (amphibian)~|~syncope, ctcae 5.0~|~thyroid diagnostic radiopharmaceuticals~|~usual severity dizziness~|~without~|~include - setoperator~|~medication - hl7 publishing domain~|~mmhg~|~0.09~|~abnormal mental state~|~age~|~age:time:point in time:^patient:quantitative~|~amount type - rate~|~basal diet~|~bothered by vomiting~|~chest pain:finding:point in time:^patient:ordinal~|~definitely related to intervention~|~diet (animal life circumstance)~|~feeding difficulties~|~feeding poor~|~have been vomiting~|~how much distress vomiting~|~how often vomiting~|~language ability - sign~|~physical findings~|~possible~|~possible diagnosis~|~possibly related to intervention~|~rate~|~rating (action)~|~relate - vinyl resin~|~related personal status~|~relationships~|~role link type - related~|~special diet therapy~|~usage~|~use - dosing instruction imperative~|~usual severity vomiting~|~vomiting, ctcae~|~diet - supply~|~seconds~|~utilization qualifier
adenosine~|~digoxin~|~supraventricular tachycardia~|~wolff-parkinson-white syndrome~|~dyspnea~|~syncope~|~lethargy~|~poverty~|~vertigo~|~energy drinks~|~dizziness~|~chest pain~|~diet therapy~|~ablepharon-macrostomia syndrome~|~androgen binding protein~|~decongestants~|~ingestion~|~thyroid (usp)~|~diet~|~cardiomyopathies~|~pulmonary edema~|~shock~|~thyroid gland~|~history of present illness~|~medical history~|~medications~|~past history of~|~thyroid diseases~|~accelerator mass spectrometry~|~aspects of signs~|~cchcr1 wt allele~|~cardiac flutter~|~chemotherapeutic perfusion~|~congenital heart disease~|~digoxin measurement~|~dizziness, ctcae 3.0~|~dizziness, ctcae 5.0~|~dyspnea, ctcae~|~electrocardiogram finding~|~fbl gene~|~flutter (respiratory device)~|~have dizziness~|~how much distress dizziness~|~how often dizzy~|~increased sweating~|~international metastatic renal cell carcinoma database consortium (imdc) criteria - poor-risk group~|~language proficiency - poor~|~lethargy, ctcae~|~microcephaly, epilepsy, and diabetes syndrome~|~manufactured sign~|~palpitations~|~palpitations, ctcae~|~patient condition code - poor~|~perfusion (biological)~|~perfusion (procedure)~|~perfusion route~|~pharmaceutical preparations~|~pills~|~poor - grade value~|~poor - qualifier~|~pulmonary edema, ctcae~|~shbg wt allele~|~specimen quality - poor~|~supraventricular tachycardia by ecg finding~|~syncope (amphibian)~|~syncope, ctcae 5.0~|~systolic blood pressure measurement~|~thyroid diagnostic radiopharmaceuticals~|~twist2 wt allele~|~usual severity dizziness~|~medication - hl7 publishing domain~|~mmhg~|~0.09~|~age~|~age:time:point in time:^patient:quantitative~|~amount type - rate~|~basal diet~|~chest pain:finding:point in time:^patient:ordinal~|~definitely related to intervention~|~diet (animal life circumstance)~|~physical findings~|~possible~|~possible diagnosis~|~possibly related to intervention~|~rate~|~rating (action)~|~relate - vinyl resin~|~related personal status~|~relationships~|~role link type - related~|~special diet therapy~|~usage~|~use - dosing instruction imperative~|~diet - supply~|~seconds~|~utilization qualifier
cardiac arrest~|~any~|~any data type~|~post~|~rhythm~|~rhythmic process (biological)~|~patients~|~cardiac arrest, ctcae 5~|~disabled person code - patient~|~electrocardiogram finding~|~exist~|~in addition to~|~mail claim party - patient~|~palpable~|~post device~|~radial pulse, function~|~received therapy or drug for~|~relationship modifier - patient~|~report source - patient~|~return of spontaneous circulation~|~return of spontaneous circulation:finding:point in time:^patient:nominal~|~slc35g1 gene~|~specimen source codes - patient~|~specimen type - patient~|~status post~|~veterinary patient~|~with - dosing instruction fragment~|~carotid~|~non mouse~|~negation
premature ventricular contractions~|~syncope~|~vertigo~|~central nervous system stimulants~|~drug overdose~|~dyspnea~|~cardiac arrhythmia~|~dizziness~|~chest pain~|~defibrillators~|~ingestion~|~andorra~|~cardiomyopathies~|~premature ventricular contraction, ctcae~|~premature ventricular contractions:num:procedure dur:heart:qn:ekg~|~heart diseases~|~and~|~and - dosing instruction fragment~|~congenital mesh qualifier~|~congenital qualifier~|~dizziness, ctcae 3.0~|~dizziness, ctcae 5.0~|~have dizziness~|~how much distress dizziness~|~how often dizzy~|~illness (finding)~|~implanted medical device (finding)~|~implants~|~including (qualifier)~|~increased sweating~|~known~|~more~|~numerous~|~pacerr gene~|~paired ventricular premature complexes~|~per minute~|~rubcnl gene~|~recent infection~|~relationshipconjunction - and~|~stimulant~|~syncope (amphibian)~|~syncope, ctcae 5.0~|~toxin~|~triplet multiple birth~|~usual severity dizziness~|~weakness~|~chest pain:finding:point in time:^patient:ordinal~|~event qualification - overdose~|~overdose~|~six
tachycardia, ventricular~|~unconscious state~|~ventricular fibrillation~|~drug overdose~|~apnea~|~cardiac arrest~|~time~|~airway obstruction~|~drug abuse~|~arrested progression~|~encounter due to problems related to other legal circumstances - arrest~|~law enforcement arrest~|~data types - time~|~time (foundation metadata concept)~|~value type - time~|~trauma~|~absent pulse~|~abuse~|~agonal respiration~|~apnea, ctcae~|~before~|~cdisc events class~|~downward~|~event~|~event unit~|~hypothermia (central) (local)~|~hypothermia due to exposure~|~hypothermia, ctcae~|~hypothermia, natural~|~leading~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pharmaceutical preparations~|~suspected diagnosis~|~suspected qualifier~|~trauma, nursing specialty~|~traumatic injury~|~ventricular fibrillation by ecg finding~|~ventricular fibrillation, ctcae 3.0~|~ventricular fibrillation, ctcae 5.0~|~ventricular tachycardia by ecg finding~|~ventricular tachycardia, ctcae 3.0~|~ventricular tachycardia, ctcae 5.0~|~victim of abuse finding~|~wounds and injuries~|~trauma qualifier~|~event qualification - overdose~|~overdose~|~possible~|~possible diagnosis~|~possibly related to intervention~|~unconscious personality factor
tachycardia~|~dyspnea~|~cardiac arrhythmia~|~dizziness~|~chest pain~|~ablepharon-macrostomia syndrome~|~artificial cardiac pacemaker~|~defibrillators~|~palpation~|~kidney failure~|~systolic pressure~|~accelerator mass spectrometry~|~congenital heart disease~|~conscious~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pacemaker ecg assessment~|~pacemaker procedure~|~pacemakers~|~palpitations~|~palpitations, ctcae~|~pharmaceutical preparations~|~specimen source codes - pacemaker~|~twist2 wt allele~|~weakness~|~mmhg~|~0.09~|~age~|~age:time:point in time:^patient:quantitative~|~alert~|~alert note~|~alert:type:point in time:^patient:nominal~|~chest pain:finding:point in time:^patient:ordinal~|~consciousness clear~|~how true feel alert right now~|~renal failure, ctcae~|~sustained ventricular tachycardia~|~system alert~|~seconds
lethargy~|~tachycardia~|~unconscious state~|~dyspnea~|~cardiac arrhythmia~|~dizziness~|~chest pain~|~ablepharon-macrostomia syndrome~|~artificial cardiac pacemaker~|~defibrillators~|~palpation~|~kidney failure~|~systolic pressure~|~accelerator mass spectrometry~|~congenital heart disease~|~lethargy, ctcae~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pacemaker ecg assessment~|~pacemaker procedure~|~pacemakers~|~palpitations~|~palpitations, ctcae~|~pharmaceutical preparations~|~specimen source codes - pacemaker~|~twist2 wt allele~|~weakness~|~mmhg~|~0.09~|~age~|~age:time:point in time:^patient:quantitative~|~chest pain:finding:point in time:^patient:ordinal~|~renal failure, ctcae~|~sustained ventricular tachycardia~|~unconscious personality factor~|~seconds
cold temperature~|~temperature~|~shivering~|~pain~|~bradycardia~|~drug overdose~|~body temperature~|~sepsis~|~flatulence~|~septicemia~|~submersion~|~glycation end products, advanced~|~andorra~|~chills~|~cyanosis~|~hypotension~|~shock~|~exposure to~|~congenital abnormality~|~immersion~|~viral nucleocapsid location~|~accident due to exposure to weather conditions~|~and~|~and - dosing instruction fragment~|~bradycardia by ecg finding~|~core~|~core device~|~core specimen~|~cyanosis, ctcae~|~degrees fahrenheit~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~environmental wind~|~exposure domain~|~hypotension, ctcae~|~immersion investigative technique~|~immersion route of exposure~|~infection~|~infections of musculoskeletal system~|~infections:-:point in time:^patient:-~|~injury due to exposure to external cause~|~old~|~old episode~|~processor core~|~relationshipconjunction - and~|~sensory (qualifier value)~|~sepsis (invertebrate)~|~sepsis, ctcae~|~toxin~|~very~|~very much~|~wetness~|~teratologic~|~abnormal mental state~|~administration method - pain~|~adverse event associated with pain~|~antimicrobial susceptibility result~|~event qualification - overdose~|~extreme~|~extreme response~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~overdose~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~predisposition -- attribute~|~susceptible~|~usual severity pain~|~very severe~|~young
water~|~drinking water~|~submersion~|~apnea~|~dyspnea~|~rales~|~rhonchi~|~stridor~|~vital signs~|~vomiting~|~wheezing~|~water - specimen source codes~|~water specimen~|~immersion~|~trauma~|~absent~|~apnea, ctcae~|~basilar rales~|~coughing~|~decreased~|~decreasing~|~deep (qualifier value)~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~dyspnea, ctcae~|~immersion investigative technique~|~immersion route of exposure~|~mental status change~|~pharyngeal stripping wave absent~|~reduced~|~regardless~|~stridor, ctcae~|~trauma, nursing specialty~|~traumatic injury~|~wounds and injuries~|~around~|~trauma qualifier~|~bothered by vomiting~|~have been vomiting~|~how much distress vomiting~|~how often vomiting~|~possible~|~possible diagnosis~|~possibly related to intervention~|~taking vital signs~|~usual severity vomiting~|~vital signs domain~|~vital signs:finding:point in time:^patient:narrative:observed~|~vomiting, ctcae~|~wheezing, ctcae
urticaria~|~dyspnea~|~erythema~|~pruritus~|~communicable diseases~|~dental occlusion~|~allergic reaction~|~wheezing~|~contusions~|~hypotension~|~shock~|~edema~|~exanthema~|~hypersensitivity~|~patients~|~adverse event associated with infection~|~allergic reaction, ctcae~|~bruising, ctcae~|~description~|~disabled person code - patient~|~dyspnea, ctcae~|~gdc type terminology~|~hypotension, ctcae~|~in addition to~|~infection~|~mail claim party - patient~|~medical device break~|~product description/appearance~|~red color~|~redness~|~relationship modifier - patient~|~report source - patient~|~sgcg gene~|~specimen source codes - patient~|~specimen type - patient~|~stinging sensation~|~type - parameterizeddatatype~|~type - attribute~|~veterinary patient~|~with - dosing instruction fragment~|~bite (event)~|~burning sensation~|~burning sensation quality~|~cep70 gene~|~evidence of (contextual qualifier)~|~have itch~|~how much distress itching~|~how often itching~|~smoking method of administration~|~specimen source codes - bite~|~sting injury~|~swelling~|~tmem173 gene~|~tmem173 wt allele~|~usual severity itching~|~wheezing, ctcae~|~wound pain~|~bite injury
temperature~|~sweating~|~muscle cramp~|~tachycardia~|~vertigo~|~seizures~|~ethanol~|~dizziness~|~environment~|~ability~|~fever~|~regulation~|~syncopal episode~|~thyroid (usp)~|~glycation end products, advanced~|~exposure to~|~andorra~|~thyroid gland~|~fatigue~|~recent~|~very~|~very much~|~alcohols~|~thyroid diseases~|~absent~|~accident due to exposure to weather conditions~|~alcohol - recreational drug use code~|~and~|~and - dosing instruction fragment~|~cramping sensation quality~|~dizziness, ctcae 3.0~|~dizziness, ctcae 5.0~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~ethanol measurement~|~exertion~|~exhaustion~|~exposure domain~|~have dizziness~|~how much distress dizziness~|~how often dizzy~|~hydration status~|~hydration status:finding:point in time:^patient:nominal~|~illness (finding)~|~increase~|~increased~|~injury due to exposure to external cause~|~medications~|~old~|~old episode~|~pharmaceutical preparations~|~regulation of biological process~|~relationshipconjunction - and~|~thyroid diagnostic radiopharmaceuticals~|~tachycardia by ecg finding~|~traumatic and/or non-traumatic injury~|~traumatic injury~|~usual severity dizziness~|~weakness~|~hyperthermia treatment~|~medication - hl7 publishing domain~|~abnormal mental state~|~and/or~|~antimicrobial susceptibility result~|~drug usage~|~fatigue subordinate domain~|~fatigue, ctcae 5.0~|~feel fatigue~|~high humidity~|~lengthened (qualifier value)~|~predisposition -- attribute~|~prolonged~|~prolonged release mechanism of action~|~susceptible~|~young
pain~|~myalgia~|~multiple endocrine neoplasia~|~vomiting~|~blood~|~gastroesophageal reflux disease~|~muscle cramp~|~movement~|~cysteamine~|~abdominal pain~|~diarrhea~|~electromagnetic radiation~|~family~|~peritonitis~|~dysuria~|~headache~|~flank pain~|~constipation~|~heartburn~|~nausea~|~symptoms~|~fever~|~radiating pain~|~emesis (eukaryote)~|~emesis [pe]~|~vomitus~|~history~|~pathological dilatation~|~diarrhea, ctcae~|~have diarrhea~|~how much distress diarrhea~|~how often diarrhea~|~in addition to~|~increase~|~increased~|~last~|~usual severity diarrhea~|~with - dosing instruction fragment~|~administration method - pain~|~adverse event associated with pain~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~usual severity pain~|~radiation~|~friend~|~travel~|~time~|~abdomen distended~|~abdominal bloating~|~acid reflux~|~anatomic site~|~associated symptom~|~bloating, ctcae~|~bothered by nausea~|~bowl dosing unit~|~bowling (activity)~|~bowls (device)~|~changed status~|~changing~|~concept history~|~constant (qualifier)~|~constant - dosing instruction fragment~|~constipation, ctcae~|~cough frequency~|~cough, ctcae~|~coughing~|~coverage level - family~|~cramping sensation quality~|~distention~|~dull~|~dull pain~|~dull sensation quality~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~dysuria, ctcae~|~entity name part type - family~|~etiology~|~etiology aspects~|~family (taxonomic)~|~family collection~|~feel nausea~|~friends - (religious affiliation)~|~have been coughing~|~have constipation~|~have nausea~|~headache, ctcae~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~how much distress constipation~|~how much distress cough~|~how much distress nausea~|~how much nausea during this period~|~how often constipation~|~how often nausea~|~improvement~|~in blood~|~intermittent~|~last name~|~living arrangement - family~|~location~|~location of oral residue following swallowing~|~location of pharyngeal residue following swallowing~|~mea1 gene~|~malaise~|~malaise, ctcae~|~mea <moth>~|~medical~|~medical history~|~medical referral type~|~medical school type~|~medical service~|~menstrual history~|~nausea subscale~|~nausea visual analogue scale~|~nausea, ctcae 3.0~|~nausea, ctcae 5.0~|~nausea:presence or threshold:point in time:^patient:ordinal~|~palpitations~|~patient outcome - worsening~|~radiation ionizing radiotherapy~|~radiotherapy research~|~rash and dermatitis associated with radiation excluding chemoradiation, ctcae~|~rebound tenderness~|~recent injury~|~spen gene~|~spen wt allele~|~science of etiology~|~sharp sensation quality~|~similarity~|~symptoms aspect~|~therapeutic radiology procedure~|~transaction counts and value totals - location~|~unit of radiation dose~|~usual severity constipation~|~usual severity cough~|~usual severity nausea~|~weakness~|~worse~|~worsening pattern~|~location participation type~|~peripheral blood~|~surgical history~|~travel charge~|~abdominal pain, ctcae 5~|~bothered by vomiting~|~data types - time~|~fever symptoms (finding)~|~fever, ctcae~|~flank pain, ctcae~|~have been vomiting~|~how much distress vomiting~|~how often vomiting~|~time (foundation metadata concept)~|~usual severity vomiting~|~value type - time~|~vomiting, ctcae
hallucinations~|~confusion~|~violence~|~drug overdose~|~diabetes mellitus~|~receptor for advanced glycation endproducts~|~delusions~|~fever~|~mok protein, human~|~rage~|~self-injurious behavior~|~anxiety~|~anger~|~anxiety disorders~|~gene expression~|~aggression scale (basc-2)~|~aggressive behavior~|~agitation~|~agitation, ctcae 3.0~|~agitation, ctcae 5.0~|~anxiety scale (basc-2)~|~anxiety visual analogue scale~|~anxiety, ctcae 3.0~|~anxiety, ctcae 5.0~|~bizarre behavior~|~change -- procedure~|~changed status~|~changing~|~clouded consciousness~|~confusion, ctcae 3.0~|~confusion, ctcae 5.0~|~crisis~|~delta (difference)~|~diabetes~|~expression (foundation metadata concept)~|~expression - value symbols~|~expression procedure~|~hallucinations, ctcae~|~homicidal thoughts~|~known~|~medical~|~medical referral type~|~medical school type~|~medical service~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~mental disorders~|~others - allergy~|~pharmaceutical preparations~|~substance abuse problem~|~suicidal~|~combative~|~hyperthermia treatment~|~other medicated shampoos in atc~|~threat~|~violent~|~ager gene~|~ager wt allele~|~absence of pain sensation~|~affect (mental function)~|~event qualification - overdose~|~fear (mental process)~|~mok gene~|~mok wt allele~|~overdose~|~pain sensitivity quantitative trait locus 1~|~self-harm
urticaria~|~age of onset~|~deglutition disorders~|~dyspnea~|~erythema~|~pruritus~|~ablepharon-macrostomia syndrome~|~food allergy~|~stridor~|~insect sting~|~wheezing~|~allergens~|~andorra~|~chest~|~exanthema~|~history~|~hypotension~|~shock~|~exposure to~|~accelerator mass spectrometry~|~accident due to exposure to weather conditions~|~act relationship subset - previous~|~allergen (brand of diphenylpyraline)~|~anatomic site~|~and~|~and - dosing instruction fragment~|~anterior thoracic region~|~concept history~|~cutaneous route of drug administration~|~dermal - anatomy qualifier~|~dyspnea, ctcae~|~eruptions~|~exposure domain~|~feeling of throat tightness~|~food allergy allergen~|~have difficulty swallowing~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~how much distress difficulty swallowing~|~how often difficulty swallowing~|~hypotension, ctcae~|~ige-mediated food allergy~|~injury due to exposure to external cause~|~location~|~location of oral residue following swallowing~|~location of pharyngeal residue following swallowing~|~medical history~|~medications~|~onset of (contextual qualifier)~|~pharmaceutical preparations~|~previous~|~recent~|~red color~|~redness~|~relationshipconjunction - and~|~stridor, ctcae~|~twist2 wt allele~|~toxic effect of venom~|~transaction counts and value totals - location~|~usual severity difficulty swallowing~|~location participation type~|~medication - hl7 publishing domain~|~have itch~|~how much distress itching~|~how often itching~|~insect sting preparation~|~usual severity itching~|~wheezing, ctcae
lethargy~|~dehydration~|~desiccation~|~baseline dental cement~|~hyperglycemia~|~hypoglycemia~|~irritable mood~|~negative surgical margin~|~pharmaceutical preparations~|~mental status, ctcae~|~mental state~|~mental status:finding:point in time:^patient:narrative:observed~|~mental status:finding:point in time:^patient:nominal:observed~|~pharmacologic substance~|~skin~|~baseline~|~bizarre behavior~|~cdisc events class~|~changed status~|~changing~|~clear~|~cool - action~|~decreased~|~decreasing~|~dehydration procedure~|~dehydration, ctcae~|~diaphoretic~|~entire skin~|~epidermal cgvhd score 0~|~event~|~event unit~|~feels warm~|~glucose in blood specimen above reference range~|~hyperglycemia, ctcae~|~hypoglycemia, ctcae~|~irritability, ctcae~|~irritation - emotion~|~kussmaul's respiration~|~lethargy, ctcae~|~mechanism (attribute)~|~mechanism component of device~|~medical history~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pmh - past medical history~|~recent~|~reduced~|~regulatory report~|~remote control command - clear~|~report (document)~|~report:finding:point in time:{setting}:document:{role}~|~reporting~|~skin specimen~|~skin specimen source code~|~skin, human~|~specimen condition - cool~|~unresponsive to treatment~|~without~|~baseline - tablecellverticalalign~|~toxic ingestion~|~unresponsive behavior~|~warming process~|~aspects of signs~|~dry~|~dry skin~|~dryness (characteristic)~|~entity handling - dry~|~hhat gene~|~manufactured sign~|~manufactured ski~|~physical findings~|~ski anatomical site notation for tumour staging~|~ski gene~|~special handling code - dry
paresthesia~|~post-traumatic stress disorder~|~hyperventilation~|~hand~|~andorra~|~anxiety~|~anxiety disorders~|~agitation~|~agitation, ctcae 3.0~|~agitation, ctcae 5.0~|~and~|~and - dosing instruction fragment~|~anxiety scale (basc-2)~|~anxiety visual analogue scale~|~anxiety, ctcae 3.0~|~anxiety, ctcae 5.0~|~carpopedal spasm~|~crisis~|~has tingling sensation~|~history of present illness~|~medical history~|~past history of~|~perioral~|~recent~|~relationshipconjunction - and~|~traumatic event
epistaxis~|~hematemesis~|~hemoptysis~|~abdominal pain~|~hematochezia~|~vomiting~|~blood coagulation disorders~|~blood platelet disorders~|~contusions~|~hemorrhage~|~hypovolemia~|~massive~|~actual blood loss~|~blood loss~|~bloody~|~bruising, ctcae~|~coffee ground vomiting~|~due to~|~epistaxis, ctcae~|~etiology~|~etiology aspects~|~extensive~|~hemophilia, nos~|~hemorrhagic~|~individual cancer history~|~is there a cancer history~|~medical~|~medical referral type~|~medical school type~|~medical service~|~science of etiology~|~abdominal pain, ctcae 5~|~blood in stool~|~bothered by vomiting~|~have been vomiting~|~how big a problem is bloody stools~|~how much distress vomiting~|~how often vomiting~|~low platelet count~|~rectal hemorrhage~|~secondary to~|~usual severity vomiting~|~vomiting, ctcae~|~anticoagulant use
oliguria~|~poverty~|~tachycardia~|~vertigo~|~dizziness~|~desiccation~|~alcohol abuse~|~anorexia~|~diarrhea~|~nausea~|~fever~|~vomiting~|~hypovolemia~|~malnutrition~|~mucous membrane~|~anorexia, ctcae~|~bothered by nausea~|~compensated~|~decreased urine output~|~diarrhea, ctcae~|~dizziness, ctcae 3.0~|~dizziness, ctcae 5.0~|~exertion~|~feel nausea~|~have diarrhea~|~have dizziness~|~have nausea~|~how much distress diarrhea~|~how much distress dizziness~|~how much distress nausea~|~how much nausea during this period~|~how often diarrhea~|~how often dizzy~|~how often nausea~|~illness (finding)~|~international metastatic renal cell carcinoma database consortium (imdc) criteria - poor-risk group~|~language proficiency - poor~|~loss of appetite (finding)~|~nausea subscale~|~nausea visual analogue scale~|~nausea, ctcae 3.0~|~nausea, ctcae 5.0~|~nausea:presence or threshold:point in time:^patient:ordinal~|~patient condition code - poor~|~poor - grade value~|~poor - qualifier~|~recent~|~skin turgor~|~specimen quality - poor~|~tachycardia by ecg finding~|~uncompensated~|~usual severity diarrhea~|~usual severity dizziness~|~usual severity nausea~|~weakness~|~and/or~|~bothered by vomiting~|~dry~|~dry skin~|~dryness (characteristic)~|~entity handling - dry~|~excessive exercise (finding)~|~fever symptoms (finding)~|~fever, ctcae~|~have been vomiting~|~how much distress vomiting~|~how often vomiting~|~lengthened (qualifier value)~|~prolonged~|~prolonged release mechanism of action~|~special handling code - dry~|~usual severity vomiting~|~vomiting, ctcae
polyuria~|~tachycardia~|~abdominal pain~|~dehydration~|~tachypnea~|~polydipsia~|~hyperphagia~|~history~|~hypotension~|~concept history~|~dehydration procedure~|~dehydration, ctcae~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~hypotension, ctcae~|~in addition to~|~increased sweating~|~known~|~kussmaul's respiration~|~lrba gene~|~last~|~meal (occasion for eating)~|~medical history~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pharmaceutical preparations~|~presentation~|~symptomatic~|~tachycardia by ecg finding~|~with - dosing instruction fragment~|~new onset~|~abdominal pain, ctcae 5~|~abnormal mental state~|~dietary indiscretion~|~two hundred fifty~|~mg/dl
hunger~|~tremor~|~malnutrition~|~drug abuse~|~infant, newborn~|~history~|~lrba gene~|~mg/dl~|~absent~|~abuse~|~concept history~|~excessive~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~hypothermia (central) (local)~|~hypothermia due to exposure~|~hypothermia, ctcae~|~hypothermia, natural~|~in addition to~|~increased sweating~|~known~|~meal (occasion for eating)~|~medical history~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~pharmaceutical preparations~|~presentation~|~recent~|~symptomatic~|~victim of abuse finding~|~weakness~|~with - dosing instruction fragment~|~with intensity~|~new onset~|~abnormal mental state~|~insulin used
antipsychotic agents~|~tardive dyskinesia~|~muscle cramp~|~pain~|~spasm~|~human body~|~tongue~|~ingestion~|~phenothiazine~|~pharmaceutical preparations~|~recent~|~neck~|~protrusion~|~adult human body~|~body of stomach~|~body structure~|~change -- procedure~|~changed status~|~changing~|~delta (difference)~|~document body~|~drug-induced tardive dyskinesia~|~drugs - dental services~|~entire~|~entire neck~|~entire tongue~|~gaze~|~human body structure~|~increase~|~kantr gene~|~known~|~medications~|~muscle twitch~|~neck of pancreas~|~neck of urinary bladder~|~phenothiazine measurement~|~phenothiazine [epc]~|~residue on tongue~|~spatial displacement~|~whole~|~whole body~|~dendritic spine neck~|~dystonic reaction~|~facial muscle spasm~|~medication - hl7 publishing domain~|~abdominal rigidity~|~administration method - pain~|~adverse event associated with pain~|~definitely related to intervention~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~relate - vinyl resin~|~related personal status~|~relationships~|~role link type - related~|~twisted~|~usual severity pain~|~convoluted shape~|~fluphenazines
temperature~|~myalgia~|~abdominal pain~|~body temperature~|~erythema~|~communicable diseases~|~dysuria~|~headache~|~chest pain~|~flushing~|~symptoms~|~sore throat~|~chills~|~exanthema~|~adverse event associated with infection~|~associated symptom~|~chills, ctcae~|~cough frequency~|~cough, ctcae~|~coughing~|~dysuria, ctcae~|~eruptions~|~feels warm~|~have been coughing~|~headache, ctcae~|~how much distress cough~|~infection~|~like~|~myalgia, ctcae 5~|~red color~|~redness~|~rigor - temperature-associated observation~|~symptoms aspect~|~usual severity cough~|~weakness~|~around~|~sweaty~|~warming process~|~101 mouse~|~abdominal pain, ctcae 5~|~abnormal mental state~|~chest pain:finding:point in time:^patient:ordinal~|~rhinovirus serotype 101
lethargy~|~tachycardia~|~ingestion~|~bradycardia~|~seizures~|~ablepharon-macrostomia syndrome~|~injection~|~alcohol consumption~|~andorra~|~hypotension~|~medications~|~pharmaceutical preparations~|~medication - hl7 publishing domain~|~illicit drugs~|~accelerator mass spectrometry~|~access~|~accident due to exposure to weather conditions~|~accidental ingestion~|~and~|~and - dosing instruction fragment~|~availability of~|~biological absorption~|~bradycardia by ecg finding~|~chemicals~|~data type - quantity~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~energy absorption~|~exposure domain~|~exposure to~|~hypertension, ctcae~|~hypertensive disease~|~hypotension, ctcae~|~inhalation dosing unit~|~inhalation method of administration~|~inhalation route of drug administration~|~injection dosing unit~|~injection method of administration~|~injection route of drug administration~|~injection of therapeutic agent~|~injection procedure~|~injury due to exposure to external cause~|~inspiration function~|~known~|~lethargy, ctcae~|~mdf attribute type - quantity~|~material absorption~|~numerous~|~pharmaceutical substances~|~pharmacokinetics: absorption~|~process of absorption~|~quantity~|~relationshipconjunction - and~|~role class - access~|~suspected diagnosis~|~suspected qualifier~|~twist2 wt allele~|~tachycardia by ecg finding~|~toxin~|~unresponsive to treatment~|~combative~|~intent~|~route of exposure~|~unresponsive behavior~|~victim~|~non mouse~|~negation~|~slow respiration~|~x-ray exposure time
seizures~|~lethargy~|~unconscious state~|~age of onset~|~oral cavity~|~back~|~craniocerebral trauma~|~tonic-clonic epilepsy~|~aura~|~clonic seizures~|~epilepsy~|~seizures, focal~|~back structure, excluding neck~|~back structure, including back of neck~|~dorsal~|~entire back (surface region)~|~trauma~|~aurka gene~|~aurka wt allele~|~bystander~|~count of entities~|~data type interval~|~decreased~|~decreasing~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~from~|~history of present illness~|~incontinence~|~interval~|~lucid~|~mdf attributetype - number~|~medical history~|~numbers~|~observed~|~onset of (contextual qualifier)~|~oral~|~oral (intended site)~|~oral dosage form~|~oral route of drug administration~|~parameterized data type - interval~|~past history of~|~post-ictal state~|~reduced~|~tonics~|~tongue biting~|~tonic - clonic seizures~|~trauma, nursing specialty~|~traumatic injury~|~wounds and injuries~|~new onset~|~seizure activity~|~trauma qualifier~|~abnormal mental state~|~visual changes
myalgia~|~vision~|~communicable diseases~|~tachycardia~|~acetaminophen~|~abdominal pain~|~erythema~|~hospitalization~|~sepsis~|~diabetes mellitus~|~hiv~|~dysuria~|~headache~|~ibuprofen~|~chest pain~|~transplantation~|~androgen binding protein~|~fever~|~flushing~|~malignant neoplasms~|~septicemia~|~sore throat~|~andorra~|~chills~|~exanthema~|~hypotension~|~adverse event associated with infection~|~infection~|~recent~|~immunocompromised host~|~transplant~|~acetaminophen assay~|~acetaminophen [epc]~|~and~|~and - dosing instruction fragment~|~associated symptom~|~bedridden~|~cchcr1 wt allele~|~cancer genus~|~cancer:-:point in time:^patient:-~|~chemotherapeutic perfusion~|~chills, ctcae~|~cough frequency~|~cough, ctcae~|~coughing~|~decreased~|~decreasing~|~diabetes~|~duration~|~duration (temporal concept)~|~duration brand of oxymetazoline~|~dysuria, ctcae~|~eruptions~|~facilitated oscillatory release technique~|~feels warm~|~fix~|~flu like symptoms, ctcae~|~hiv vaccine~|~have been coughing~|~headache, ctcae~|~history of present illness~|~how much distress cough~|~human immunodeficiency virus measurement~|~hypotension, ctcae~|~immobile~|~influenza-like symptoms~|~intake~|~last~|~medical history~|~myalgia, ctcae 5~|~past history of~|~perfusion (biological)~|~perfusion (procedure)~|~perfusion route~|~preposition for~|~primary malignant neoplasm~|~red color~|~redness~|~reduced~|~relationshipconjunction - and~|~rigor - temperature-associated observation~|~shbg wt allele~|~sepsis (invertebrate)~|~sepsis, ctcae~|~severities~|~source~|~source (property) (qualifier value)~|~specialty type - cancer~|~systolic blood pressure measurement~|~tachycardia by ecg finding~|~term source~|~usual severity cough~|~wwox gene~|~wwox wt allele~|~weakness~|~with intensity~|~around~|~mmhg~|~sweaty~|~warming process~|~abdominal pain, ctcae 5~|~abnormal mental state~|~age~|~age:time:point in time:^patient:quantitative~|~chest pain:finding:point in time:^patient:ordinal~|~evidence of (contextual qualifier)~|~transplanted tissue
dyspnea~|~hemoptysis~|~respiratory sounds~|~work of breathing~|~tachypnea~|~negative surgical margin~|~rales~|~rhonchi~|~stridor~|~wheezing~|~history~|~thoracic injuries~|~absent~|~accessory skeletal muscle~|~accident due to exposure to weather conditions~|~basilar rales~|~clear~|~concept history~|~cough frequency~|~cough, ctcae~|~coughing~|~decreased~|~decreasing~|~dyspnea, ctcae~|~epidermal cgvhd score 0~|~etiology~|~etiology aspects~|~event seriousness - significant~|~exposure domain~|~exposure to~|~have been coughing~|~have shortness of breath question~|~historical aspects qualifier~|~history of present illness~|~history of previous events~|~how much distress cough~|~how much distress shortness of breath~|~how often shortness of breath~|~injury due to exposure to external cause~|~medical history~|~pharyngeal stripping wave absent~|~pursed lips~|~recent~|~reduced~|~remote control command - clear~|~science of etiology~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~significant~|~specimen source codes - respiratory~|~statistical significance~|~stridor, ctcae~|~toxic~|~toxic effect~|~tripod position~|~usual severity cough~|~usual severity shortness of breath~|~without~|~new onset~|~respiratory~|~abnormal breath sounds~|~possible~|~possible diagnosis~|~possibly related to intervention~|~usage~|~use - dosing instruction imperative~|~wheezing, ctcae~|~utilization qualifier
air~|~angiotensin-converting enzyme inhibitors~|~airway obstruction~|~cyanosis~|~recent~|~angiotensin-converting enzyme inhibitor (disposition)~|~cdisc events class~|~cdisc sdtm anatomical location terminology~|~cyanosis, ctcae~|~decreased~|~decreasing~|~event~|~event unit~|~exchange (clinical)~|~inadequate (qualifier)~|~level of consciousness~|~location~|~partial~|~reduced~|~target awareness - partial~|~unsatisfactory~|~angiotensin-converting enzyme inhibitor activity~|~degree of relationship - exchange~|~foreign body aspiration~|~acute insulin response~|~ai/rheum~|~airn gene~|~air (substance)~|~complete~|~complete pharyngeal contraction~|~completion status for valid values - complete~|~data operation - complete~|~finish - dosing instruction imperative~|~secondary to~|~usage~|~use - dosing instruction imperative~|~utilization qualifier
bronchitis, chronic~|~oxygen~|~continuous positive airway pressure~|~work of breathing~|~dyspnea~|~tachypnea~|~chronic obstructive airway disease~|~lymphoid interstitial pneumonia~|~rhonchi~|~stridor~|~wheezing~|~allergens~|~andorra~|~smoke~|~respiration~|~chronic obstructive pulmonary disease of horses~|~allergens identified:presence or identity:point in time:serum:nominal~|~arcn1 gene~|~ability to speak~|~accessory skeletal muscle~|~address type - home~|~administration procedure~|~and~|~and - dosing instruction fragment~|~biomaterial treatment~|~cenpj gene~|~chemicals~|~decreased~|~decreasing~|~entire lip~|~exertion~|~expiration, function~|~exposure to~|~gdc lymphatic invasion present terminology~|~h/o: asthma~|~have shortness of breath question~|~home environment~|~how much distress shortness of breath~|~how often shortness of breath~|~lip structure~|~machine~|~medical device emits smoke~|~medications~|~medications:-:point in time:^patient:-~|~medications:presence or identity:duration of the study:^patient:nominal~|~organization unit type - home~|~oxygen equipment location~|~person location type - home~|~pharmaceutical preparations~|~phase~|~reduced~|~relationshipconjunction - and~|~smg1 gene~|~smg1 wt allele~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~stridor, ctcae~|~therapeutic procedure~|~tobacco smoke~|~treating~|~treatment epoch~|~treatment study~|~trial phase~|~usual severity shortness of breath~|~visit user code - home~|~home health encounter~|~therapeutic aspects~|~treatment - actinformationmanagementreason~|~breathing distress question~|~inspiration function~|~lengthened (qualifier value)~|~prolonged~|~prolonged release mechanism of action~|~reactive airway disease~|~usage~|~use - dosing instruction imperative~|~wheezing, ctcae~|~respiratory gaseous exchange in organisms~|~utilization qualifier
bronchitis, chronic~|~continuous positive airway pressure~|~work of breathing~|~dyspnea~|~tachypnea~|~pulmonary emphysema~|~chronic obstructive airway disease~|~lymphoid interstitial pneumonia~|~rhonchi~|~stridor~|~wheezing~|~andorra~|~respiration~|~arcn1 gene~|~ability to speak~|~accessory skeletal muscle~|~address type - home~|~administration procedure~|~and~|~and - dosing instruction fragment~|~at home~|~biomaterial treatment~|~cenpj gene~|~chronic obstructive pulmonary disease of horses~|~decreased~|~decreasing~|~entire lip~|~exertion~|~expiration, function~|~gdc lymphatic invasion present terminology~|~have shortness of breath question~|~history of present illness~|~home environment~|~home oxygen supply~|~how much distress shortness of breath~|~how often shortness of breath~|~lip structure~|~machine~|~medical history~|~organization unit type - home~|~past history of~|~pathological accumulation of air in tissues~|~person location type - home~|~phase~|~reduced~|~relationshipconjunction - and~|~smg1 gene~|~smg1 wt allele~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~stridor, ctcae~|~therapeutic procedure~|~treating~|~treatment epoch~|~treatment study~|~trial phase~|~usual severity shortness of breath~|~visit user code - home~|~home health encounter~|~therapeutic aspects~|~treatment - actinformationmanagementreason~|~breathing distress question~|~inspiration function~|~lengthened (qualifier value)~|~prolonged~|~prolonged release mechanism of action~|~usage~|~use - dosing instruction imperative~|~wheezing, ctcae~|~respiratory gaseous exchange in organisms~|~utilization qualifier
bronchitis~|~upper respiratory infections~|~dyspnea~|~tachypnea~|~lymphoid interstitial pneumonia~|~rhonchi~|~fever~|~wheezing~|~andorra~|~respiration~|~upper respiratory infection, ctcae~|~work~|~ability to speak~|~accessory skeletal muscle~|~and~|~and - dosing instruction fragment~|~barking cough~|~decreased~|~decreasing~|~entire lip~|~exertion~|~gdc lymphatic invasion present terminology~|~have shortness of breath question~|~history of present illness~|~how much distress shortness of breath~|~how often shortness of breath~|~inspiratory stridor~|~lip structure~|~medical history~|~past history of~|~reduced~|~relationshipconjunction - and~|~smg1 gene~|~smg1 wt allele~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~usual severity shortness of breath~|~breathing distress question~|~chronic infectious disease~|~fever symptoms (finding)~|~fever, ctcae~|~inspiration function~|~usage~|~use - dosing instruction imperative~|~wheezing, ctcae~|~asthma chronic~|~respiratory gaseous exchange in organisms~|~utilization qualifier
hoarseness~|~pharyngitis~|~dyspnea~|~drooling~|~sore throat~|~stridor~|~fever~|~allergy severity - severe~|~borg category-ratio 10 perceived exertion score 5~|~epidermal cgvhd score 4~|~grade 3 severe adverse event~|~have shortness of breath question~|~hoarseness, ctcae~|~how much distress shortness of breath~|~how often shortness of breath~|~intensity and distress 5~|~severe (severity modifier)~|~severe - severity of illness code~|~severe - triage code~|~severe extremity pain~|~severe hallucination~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~sore throat brand of phenol~|~sore throat, ctcae~|~stridor, ctcae~|~usual severity shortness of breath~|~fever symptoms (finding)~|~fever, ctcae
pneumonia~|~myalgia~|~abdominal pain~|~dyspnea~|~communicable diseases~|~dysuria~|~headache~|~chest pain~|~rales~|~rhonchi~|~fever~|~sore throat~|~wheezing~|~exanthema~|~hospitals~|~respiration~|~illness (finding)~|~recent~|~specimen source codes - respiratory~|~respiratory~|~acquired (qualifier value)~|~acquired name~|~adverse event associated with infection~|~associated symptom~|~at risk for aspiration~|~basilar rales~|~cough frequency~|~cough, ctcae~|~coughing~|~dysuria, ctcae~|~eruptions~|~facilitated oscillatory release technique~|~flu like symptoms, ctcae~|~gradual onset~|~h/o: bronchitis~|~have been coughing~|~have shortness of breath question~|~headache, ctcae~|~hospital environment~|~how much distress cough~|~how much distress shortness of breath~|~how often shortness of breath~|~in addition to~|~infection~|~influenza-like symptoms~|~last~|~localized~|~month of may~|~myalgia, ctcae 5~|~not required~|~not required - hl7conformanceinclusion~|~organization unit type - hospital~|~preposition for~|~present~|~presentation~|~productive cough~|~productive cough, ctcae~|~shortness of breath visual analogue scale~|~shortness of breath:-:point in time:^patient:-~|~upper~|~usual severity cough~|~usual severity shortness of breath~|~wwox gene~|~wwox wt allele~|~with - dosing instruction fragment~|~within~|~day~|~hospital visit~|~abdominal pain, ctcae 5~|~chest pain on breathing~|~chest pain:finding:point in time:^patient:ordinal~|~fever symptoms (finding)~|~fever, ctcae~|~wheezing, ctcae
dyspnea~|~rales~|~pulmonary edema~|~basilar rales~|~bilateral~|~cdisc findings class~|~dyspnea, ctcae~|~in addition to~|~procedure findings:finding:point in time:^patient:narrative~|~pulmonary edema, ctcae~|~with - dosing instruction fragment~|~findings aspects
risk~|~syncope~|~tachycardia~|~hemoptysis~|~respiratory sounds~|~dyspnea~|~chest pain~|~recent~|~blood clot~|~embolism~|~embolus~|~negative surgical margin~|~ocular cicatricial pemphigoid~|~thrombosis~|~immobilization~|~travel~|~administration occupational activities~|~administration procedure~|~agent administration~|~clear~|~dyspnea, ctcae~|~epidermal cgvhd score 0~|~fbl gene~|~general surgery specialty~|~immobilization test~|~increase~|~jugular venous engorgement~|~level of care - surgery~|~limb structure~|~month of may~|~operative surgical procedures~|~remote control command - clear~|~subject risk~|~sudden onset (attribute)~|~sudden onset (contextual qualifier) (qualifier value)~|~surgery specialty~|~surgical aspects~|~syncope (amphibian)~|~syncope, ctcae 5.0~|~tachycardia by ecg finding~|~thrombosis of blood vessel~|~travel charge~|~chest pain:finding:point in time:^patient:ordinal~|~chest swelling~|~within 30 days~|~unilateral leg pain
comorbidity~|~chronic obstructive airway disease~|~anemia~|~body part~|~severing~|~traumatic injury~|~laceration~|~time~|~arcn1 gene~|~anemia, ctcae~|~chronic obstructive pulmonary disease of horses~|~complete~|~complete agreement~|~completely - dosing instruction fragment~|~completely able~|~contamination~|~crushing procedure~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~genus anemia~|~mechanism of injury~|~medical~|~medical device contamination during use~|~medical referral type~|~medical school type~|~medical service~|~penetration~|~specimen reject reason - contamination~|~traumatic and/or non-traumatic injury~|~adulteration~|~data types - time~|~injury wounds~|~route of administration - wound~|~specimen source codes - wound~|~specimen type - wound~|~time (foundation metadata concept)~|~value type - time
hoarseness~|~pain~|~unconscious state~|~electricity~|~bulla~|~wheezing~|~hypotension~|~shock~|~burns, inhalation~|~edema~|~contact with~|~direct (qualifier)~|~direct - postaladdressuse~|~direct type of relationship~|~lightning (phenomenon)~|~private communication address~|~source~|~source (property) (qualifier value)~|~term source~|~traumatic injury~|~chemical reaction~|~heat (physical force)~|~trauma~|~time~|~additional~|~from~|~hoarseness, ctcae~|~hypotension, ctcae~|~respiratory distress~|~tissue injury~|~trauma, nursing specialty~|~traumatic and/or non-traumatic injury~|~wounds and injuries~|~trauma qualifier~|~administration method - pain~|~adverse event associated with pain~|~blistering eruption~|~burn injury~|~data types - time~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~potential~|~swelling~|~time (foundation metadata concept)~|~usual severity pain~|~value type - time~|~wheezing, ctcae
pain~|~organ~|~hemorrhage~|~traumatic injury~|~trauma~|~act relationship checkpoint - through~|~causing~|~evisceration - action~|~through~|~trauma, nursing specialty~|~wounds and injuries~|~protrusion~|~trauma qualifier~|~administration method - pain~|~adverse event associated with pain~|~code system type - internal~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~injury wounds~|~internal~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~route of administration - wound~|~specimen source codes - wound~|~specimen type - wound~|~usual severity pain
eye~|~aids related complex~|~low vision~|~eye injuries~|~eye pain~|~pain~|~entire eye~|~corneal abrasions~|~visual impairment~|~xerostomia~|~andorra~|~chemical burns~|~in addition to~|~traumatic injury~|~with - dosing instruction fragment~|~foreign bodies~|~laceration~|~trauma~|~abnormal vision~|~and~|~and - dosing instruction fragment~|~avulsed wound~|~bed status - closed~|~closed~|~excessive tearing~|~eye specimen~|~eye specimen source code~|~foreign body (physical object)~|~have excessive tearing~|~including (qualifier)~|~orbital region~|~relationshipconjunction - and~|~resulting in~|~spray (action)~|~spray (administration method)~|~spray dosage form~|~spray dosing unit~|~spraying behavior~|~trauma, nursing specialty~|~traumatic and/or non-traumatic injury~|~unspecified visual loss~|~wounds and injuries~|~etiology unknown~|~nasal drainage~|~trauma qualifier~|~apoptosis repressor with card domain~|~arc gene~|~administration method - pain~|~adverse event associated with pain~|~arcuate shape~|~atypical reparative cell~|~burn injury~|~burning sensation~|~burning sensation quality~|~eye pain, ctcae 3.0~|~eye pain, ctcae 5.0~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~nol3 gene~|~open~|~open surgical procedure~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~radiation arc~|~smoking method of administration~|~usual severity pain
brain concussion~|~traumatic brain injury~|~pain~|~unconscious state~|~seizures~|~craniocerebral trauma~|~whole-body irradiation~|~convulsions~|~depressed level of consciousness~|~gclc protein, human~|~vomiting~|~edema~|~hemorrhage~|~trauma~|~time~|~blunt (object)~|~blunted~|~ceramide glucosyltransferase, human~|~device plate~|~etiology~|~etiology aspects~|~failure~|~failure (biologic function)~|~gclc gene~|~gclc wt allele~|~history of present illness~|~mechanism of injury~|~medical history~|~operative surgical procedures~|~past history of~|~penetration~|~personal failure~|~respiratory distress~|~resulting in~|~science of etiology~|~stent, device~|~surgical service~|~trauma, nursing specialty~|~traumatic injury~|~ugcg gene~|~ugcg wt allele~|~wounds and injuries~|~trauma qualifier~|~abnormal mental state~|~administration method - pain~|~adverse event associated with pain~|~bothered by vomiting~|~data types - time~|~feel pain~|~frequency of pain question~|~have been vomiting~|~have pain~|~how much distress pain~|~how much distress vomiting~|~how often vomiting~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~posturing~|~swelling~|~time (foundation metadata concept)~|~usual severity pain~|~usual severity vomiting~|~value type - time~|~vomiting, ctcae
unconscious state~|~ablepharon-macrostomia syndrome~|~abdominal cavity~|~abdomen~|~chest~|~hypotension~|~pelvis~|~shock~|~traumatic injury~|~abdominopelvic structure~|~accelerator mass spectrometry~|~anterior thoracic region~|~associated with~|~body tissue~|~damage~|~drug vehicle~|~entire abdomen~|~entire pelvis~|~female genital injuries~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~hypotension, ctcae~|~magee1 gene~|~male genital injuries~|~mechanism of injury~|~musculoskeletal~|~musculoskeletal:-:point in time:^patient:-~|~numerous~|~pelvic cavity structure~|~short stature, onychodysplasia, facial dysmorphism, and hypotrichosis syndrome~|~soft~|~twist2 wt allele~|~tissue specimen code~|~tissue damage~|~traumatic and/or non-traumatic injury~|~vehicle (transportation)~|~trauma qualifier~|~urologic injuries~|~unconscious personality factor
pain~|~movement~|~palpation~|~3,5-dichloro-1,4-aminophenol~|~blood circulation~|~fractures, closed~|~traumatic and/or non-traumatic injury~|~traumatic injury~|~time~|~absent~|~act relationship subset - previous~|~affected area of body~|~affected site~|~arrival - action~|~circulatory process~|~decreased~|~decreasing~|~device motor~|~esthesia~|~from~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~mechanism of injury~|~observation of sensation~|~pharyngeal stripping wave absent~|~previous~|~recent injury~|~reduced~|~sensation quality~|~arrival - actrelationshiptype~|~motor movement~|~administration method - pain~|~adverse event associated with pain~|~and/or~|~data types - time~|~distal (qualifier value)~|~distal resection margin~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~open~|~open surgical procedure~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~time (foundation metadata concept)~|~usual severity pain~|~value type - time
foreign bodies~|~ballistics~|~foreign body (physical object)~|~penetration~|~consider~|~wounds, penetrating~|~act relationship checkpoint - exit~|~any~|~any data type~|~body part~|~computer programming object~|~embedding~|~entrance~|~evaluation and management note:finding:point in time:{setting}:document:{provider}~|~exit~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~mechanism of injury~|~note (document)~|~object class~|~physical object~|~toxin~|~and/or~|~injury wounds~|~wounds - qualifier
pain~|~amnesia~|~cicatrix~|~4-hydroxybutyric acid~|~flunitrazepam~|~ketamine~|~4-butyrolactone~|~ethanol~|~dental occlusion~|~memory loss~|~rohypnol~|~gamma hydroxybutyrate~|~contusions~|~defecation~|~urination~|~edema~|~administration method - pain~|~adverse event associated with pain~|~feel pain~|~frequency of pain question~|~have pain~|~how much distress pain~|~pain distress question~|~pain by anatomic descriptor, ctcae~|~pain, ctcae~|~pain:-:point in time:^patient:-~|~usual severity pain~|~alcohols~|~genital system~|~genitalia~|~academic research enhancement awards~|~alcohol - recreational drug use code~|~area~|~aspects of signs~|~assault~|~disturbance in mood~|~drugs - dental services~|~ethanol measurement~|~exposure to~|~flunitrazepam measurement~|~geographic locations~|~in addition to~|~mlst8 gene~|~manufactured sign~|~massive~|~pharmaceutical preparations~|~recent~|~rectal (intended site)~|~rectal dosage form~|~rectal route of drug administration~|~regulatory report~|~report (document)~|~report:finding:point in time:{setting}:document:{role}~|~reporting~|~scar tissue~|~specimen source codes - genital~|~specimen type - genital~|~tube,rectal,24fr,plastic b#6510~|~traumatic and/or non-traumatic injury~|~traumatic injury~|~unexplained~|~with - dosing instruction fragment~|~date rape~|~rectal~|~bite (event)~|~cep70 gene~|~genital hemorrhage~|~physical findings~|~possible~|~possible diagnosis~|~possibly related to intervention~|~sexual assault~|~specimen source codes - bite~|~swelling~|~bite injury
numbness~|~andorra~|~hypotension~|~paralysed~|~nervous system physiological phenomena~|~and~|~and - dosing instruction fragment~|~decreased~|~decreasing~|~deferred~|~delayed release mechanism of action~|~delayed testing~|~general mechanism of the forces which caused the injury:find:pt:^patient:nom~|~hypotension, ctcae~|~inferior~|~mechanism of injury~|~neurologic (qualifier value)~|~neurological:-:point in time:^patient:-~|~present~|~reduced~|~relationshipconjunction - and~|~site of~|~table frame - below~|~traumatic and/or non-traumatic injury~|~traumatic injury~|~views delayed~|~compromise~|~elapsed time~|~time since injury
patient discharge~|~delirium~|~cardiac arrhythmia~|~taser~|~congenital abnormality~|~heart diseases~|~patients~|~chemical probe~|~dna probe method~|~delirium, ctcae~|~disabled person code - patient~|~embedding~|~facilitated oscillatory release technique~|~mail claim party - patient~|~preposition for~|~probe brand of methazole herbicide~|~probes~|~relationship modifier - patient~|~report source - patient~|~specimen source codes - patient~|~specimen type - patient~|~veterinary patient~|~wwox gene~|~wwox wt allele~|~probe gene fragment~|~teratologic~|~body fluid discharge~|~discharge, body substance, sample~|~discharge, body substance~|~excitation~|~excited~|~specimen source codes - discharge~|~usage~|~use - dosing instruction imperative~|~utilization qualifier
apnea~|~trauma qualifier~|~trauma~|~traumatic injury~|~trauma, nursing specialty~|~wounds and injuries~|~absent pulse~|~acute - triage code~|~admission level of care code - acute~|~any~|~any data type~|~blunt (object)~|~blunted~|~etiology~|~etiology aspects~|~female genital injuries~|~male genital injuries~|~operative surgical procedures~|~penetration~|~present~|~problem~|~problem:find:pt:^patient:nom~|~rhythm~|~science of etiology~|~surgical service~|~traumatic~|~acute~|~acute inpatient encounter~|~rhythmic process (biological)~|~urologic injuries~|~evidence of (contextual qualifier)~|~non mouse~|~negation